


Galacturonic Acid Lactones in the Synthesis of All Trisaccharide Repeating Units of the Zwitterionic Polysaccharide Sp1

Alphert E. Christina, Leendert J. van den Bos, Herman S. Overkleef, Gijsbert A. van der Marel,* and Jeroen D. C. Codée*

Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands

S Supporting Information

ABSTRACT:



A modular approach toward the synthesis of all possible trimer repeating units of the type 1 capsular polysaccharide of *Streptococcus pneumoniae*, Sp1, is described. This zwitterionic polysaccharide is built up from trisaccharide repeats, which in turn are composed of two galacturonic acid monomers and a 2,4,6-trideoxy-4-amino-2-acetamido-D-galactose moiety. All monomeric constituents are linked through *cis*-glycosidic bonds. To overcome the difficulty associated with the efficient stereoselective introduction of the α -galacturonic acid bonds, we have employed galacturonic acid-[3,6]-lactone building blocks. Not only did these building blocks perform well when used as donor galactosides, they were also shown to be reactive acceptor glycosides when equipped with a free hydroxyl function. All three frame-shifted trimer repeats were constructed via highly stereoselective glycosylation reactions, with one exception. The epimeric mixture of trisaccharides, formed in the nonselective glycosylation event, could be readily separated after global deprotection using high performance anion exchange chromatography (HPEAC).

INTRODUCTION

Zwitterionic polysaccharides (ZPs) present an unique class of polysaccharides from both a structural and a biological perspective.^{1,2} These bacterial polysaccharides contain both basic amino functions and acidic carboxylate groups, accommodating them with a zwitterionic character at physiological pH. This not only distinguishes them from other naturally occurring polysaccharides but also bestows them with distinctive biological activity. ZPs are the only class of polysaccharides that is capable of eliciting a T-cell-dependent immune response, a mode of action that was long thought to be confined to peptides.^{1,2} Indeed, the sole manner in which regular polysaccharides could be applied in effective vaccine formulations has been through conjugation to immunostimulatory carrier proteins.³ Without these proteins, (capsular) polysaccharides are processed by antigen presenting cells but not presented by MHC class II proteins to T-cells, a key step in the realization of adaptive immune responses. In contrast, ZPs are capable of

stimulating CD-4+ T-cell proliferation, after being presented via the MHC-II processing pathway.^{2,4,5} In addition, ZPs have also been shown to stimulate the innate immune system through interaction with the Toll-like receptor 2 (TLR2).⁶ To elucidate the mode of action of ZPs at the molecular level, well-defined ZPs fragments can serve as valuable tools.⁷ We therefore set out to develop a strategy to synthesize fragments of the *S. pneumoniae* zwitterionic polysaccharide. *S. pneumoniae* is the causative agent of pneumonia, bacteremia, otitis media, meningitis, and peritonitis,⁸ and one of its capsular polysaccharides, Sp1, is a prominent member of the ZPs family.^{4,9} Sp1 is an overall anionic polysaccharide built up from nonbranching [\rightarrow 3)- α -2,4,6-trideoxy-4-amino-D-GalNAc-(1 \rightarrow 4)- α -D-GalAp-(1 \rightarrow 3)- α -D-GalAp-(1 \rightarrow)]¹⁰ trisaccharide repeats, as depicted in Figure 1. The trimer repeat contains two α -D-galacturonic acids in addition to the rare α -2,4,

Received: November 29, 2010

Published: February 22, 2011





Figure 1. Sp1 polysaccharide and our retrosynthetic strategy toward the three frame-shifted trimer repeats 1–3.

6-trideoxy-4-amino-2-acetamido-D-galactose moiety. We here report the assembly of all three possible spacers containing Sp1 repeating units 1–3 (Figure 1).

RESULTS AND DISCUSSION

The synthesis of (fragments of) the Sp1 oligosaccharide is complicated by the presence of the uronic acid moieties and the rare 2,4,6-trideoxy-4-amino-D-GalNAc monosaccharide,^{7,11,12} which are interconnected through 1,2-*cis*-glycosidic bonds. Different approaches have been pursued for the introduction of uronic acids in oligosaccharide chains.¹³ These can be introduced at the monosaccharide level in a pre-glycosylation oxidation strategy, which uses glycuronic acid building blocks as donor and acceptor in the construction of the target oligomer. Alternatively, a post-glycosylation-oxidation approach can be followed in which the oligosaccharide backbone is built up prior to the installment of the carboxylate functions. Galacturonic acids are generally considered to be relatively poor glycosyl donors^{14,15} because of the electron-withdrawing effect of the C-5 carboxylic acid ester. Similarly, the C-5 carboxylate exerts a deactivating effect on the nucleophilicity of the proximal hydroxyl functions, which explains why the C-4 hydroxyl group in galacturonic acid acceptors has been regarded as a poor nucleophile.¹⁶ In the first synthesis of two Sp1-oligomers, Bundle and co-workers therefore resorted to the use of nonoxidized galactose building blocks in a

postglycosylation oxidation approach.¹⁵ For the synthesis of all three frame-shifted repeating units of the Sp1 saccharide, we opted for a modular strategy in which monomeric building blocks can be combined in a flexible manner, as retrosynthetically depicted in Figure 1. To limit the amount of synthetic transformations at the oligosaccharide stage, and especially avoid the late-stage multiple oxidation step, we explored the use of C-6 oxidized galactosyl building blocks. We have previously described that conformationally locked 1-thiogalacturonic acid lactone donors show excellent reactivity^{17,18} as well as anomeric selectivity in glycosylations to provide α -linked galacturonides in excellent yield.¹⁹ This makes them attractive donor glycosides in the assembly of the target Sp1-oligomers. Additionally, the inverted ¹C₄-chair conformation of the galacturonic acid-[3,6]-lactones positions the C4-OH equatorially, as opposed to the less accessible axial orientation in the normal ⁴C₁-chair.²⁰ In the synthesis of L-guluronate alginate oligomers, Hung and co-workers have shown that changing the orientation of the C4-OH of a gulosyl acceptor from an axial to an equatorial position, by locking the L-gulosyl ring in a ⁴C₁-conformation with an 1,6-anhydro bridge, increases the nucleophilicity of the C4-OH.²¹ We reasoned that the inversion of the galacturonic acid chair conformation in the lactone synthons can have a similar beneficial effect on the galacturonic acid C4-hydroxyl. Thus, for our assembly of the Sp1-repeating units we envisaged two galacturonic

Scheme 1^a

^a Reagents and conditions: (a) TBDMSCl, imidazole, DMF; (b) BnBr, NaH, DMF, 0 °C; (c) TBAF, THF, 80% (over three steps); (d) TEMPO, BAIB, DCM, H₂O, 75%; (e) TEMPO, BAIB, DCM, H₂O; (f) AcOH/H₂O (4/1 v/v), 60 °C; (g) ethyl chloroformate, DiPEA, THF, 34% (over three steps); (h) (ClAc)₂O, pyridine, DCM, quant; (i) triethylamine·3HF, THF, 98%; (j) ClC(=NPh)CF₃, Cs₂CO₃, H₂O, acetone, 83% (α/β 1:3); (k) acceptor **9**, cat. TfOH, DCM/Et₂O (1/1 v/v), 0 °C, quant (α/β 4:1); (l) thiourea, EtOH, pyridine, 65 °C, 78% for **20**, 16% for the β -anomer.

acid lactones: fully protected lactone thioglycoside **4** and acceptor lactone **5**. These will be combined with suitably protected 2,4,6-trideoxy-4-amino-D-galactosamine building blocks **6–8** bearing a nonparticipating azide functionality at C2 and a benzyloxycarbonyl (Z)-protected amine at C4 (Figure 1). In our synthetic plan, we capped the reducing ends of the trimer repeating units with a glycerol spacer.²²

Synthesis of the Building Blocks. The synthesis of the required building blocks is depicted in Scheme 1. The assembly of the galacturonic acid lactone building blocks **4** and **5** started from known β -1-thiogalactoside **10** (Scheme 1A).²³ Selective silylation of the C-3 and C-6 hydroxyls in **10** led to diol **11**,²⁴ which was used without purification in the ensuing benzylation step to provide the fully protected galactoside **12**. Desilylation of crude **12** using tetrabutylammonium fluoride in THF led to the isolation of diol **13**, which was isolated in 80% yield over the three steps. 2,2,6,6-Tetramethyl-1-piperidinyloxy (TEMPO)/[bis(acetoxy)iodo]benzene (BAIB)-mediated oxidation^{25,26} of the primary alcohol in **13** was followed by in situ lactone formation to provide the target galacturonic acid lactone **4** in one step, as we described previously.¹⁹

To construct galacturonic acid lactone acceptor **5**, β -1-thiogalactoside **10** was transformed into partially protected **14** following an one-pot procedure reported by Sinaÿ and co-workers.²⁷ TEMPO/BAIB-mediated oxidation of the primary hydroxyl and subsequent acidic hydrolysis of the acetonide gave crude acid **16**.²⁸ Lactonization of the acid was accomplished using ethyl chloroformate to generate the mixed anhydride, which cyclized to give **5** in 34% yield over the last three steps.²⁹ The concentration at which this lactonization step was performed turned out to be of vital importance to the outcome of the reaction. Insufficiently diluted conditions afforded **17** as a side





Figure 2. Schematic representation of observed crosspeaks from 2D NMR experiments with lactone building blocks **4** (a1, H₂-CH₂ Bn (HMBC); b1, H₄-CH₂ Bn (HMBC); c1, H₃-H₅ (COSY)) and **5** (a₂, H₂-CH₂ Bn (HMBC); b₂, H₄-OH (COSY); c₂, H₃-H₅ (COSY)) whereupon the assignment of peaks was based.

product, providing an indication that the equatorially oriented hydroxyl function in lactone acceptor **5** is a reactive nucleophile. The structure of the lactone building blocks **4** and **5** was fully ascertained by NMR spectroscopy using ¹H, ¹³C, ¹H-¹H COSY, and ¹H-¹³C HSQC data (Figure 2). A vicinal coupling of H-4 with 4-OH in **5** led to spectral allocation of the H-4 proton signal in the spectrum of **5**. The resonance of H-3 was assigned on the basis of its relatively large chemical shift.³⁰ Because the ¹H NMR spectrum of **5** showed a coupling of H-3 with both H-2 and H-5,³¹ the latter two protons were distinguished by a long-range ¹H-¹³C HMBC NMR experiment, in which a clear cross peak between H-2 and the benzylic carbon was revealed. In this experiment, a crosspeak between C-6 and H-3 was also observed. Chemical shift similarities in the spectra of **4** and **5**, in combination with a ¹H-¹³C HMBC NMR experiment, which revealed a crosspeak between H-4 of **4** and a benzylic carbon, led to the full assignment of the resonance sets belonging to lactone **4**.

The construction of the required 2,4,6-trideoxy-4-amino-D-galactosamine building blocks^{7,11,18,32} is outlined in Scheme 1B.

Scheme 2^a


^a Reagents and conditions: (a) 4, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 6, 75%; (b) BnOH, AcCl, 50 °C, overnight (quant); (c) (ClAc)₂O, pyridine, 93%; (d) triethylamine · 3HF, THF, 84% (α/β 1:4); (e) ClC(=NPh)CF₃, Cs₂CO₃, H₂O, acetone, 85%; (f) acceptor 5, cat. TfOH, DCM, 81% (α/β 8:1); (g) Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 9 (81%); (h) thiourea, EtOH, pyridine, 65 °C, 76%; (i) AcSH/pyridine (1/1 v/v), 94%; (j) TMSO₂Na, DCM, then H₂/Pd(C), *t*-BuOH, H₂O, HCl (52% over two steps).

We have recently reported the synthesis 2-azido-4-(benzyloxycarbonyl)amino-2,4,6-trideoxy-D-galactose building blocks in the context of the synthesis of the tetrasaccharide repeating unit of the *Bacteroides fragilis* ZPs,⁷ and building block 6 was obtained from D-glucosamine using very similar procedures.³³ Lactone 7 was obtained from 6 by chloroacetylation of the C-3 OH, followed by anomeric desilylation. From 7, donor 8 was readily obtained by installment of the *N*-phenyltrifluoroimidate function.³⁴ Imidate 8 was condensed with glycerol acceptor 9, accessible from solketal following literature procedures,³⁵ under the agency of a catalytic amount of triflic acid (TfOH) in dichloromethane to provide 19 as a 1:1 mixture of inseparable anomers. Although the use of a DCM/Et₂O solvent system in this glycosylation event led to the preferential formation of the α-anomer,³⁶ the anomers remained inseparable at this stage. Fortunately, after dechloroacetylation of 19, the epimers were separable by flash column chromatography, and 2,4,6-trideoxy-4-amino-D-galactosamine building block 20 was obtained in 78% from 19, alongside 16% of its C1-epimer.


Assembly of the Trimer Repeats. With all monomeric building blocks in hand, we set out to assemble the three frame-shifted trimer repeats 1–3. The synthesis of the first trisaccharide started with the coupling of lactone 4 and 2,4,6-trideoxy-4-amino-D-galactosamine 6 (Scheme 2). To this end, donor 4 was preactivated using in situ generated diphenylsulfonium bistriflate³⁷ and subsequently treated with acceptor 6 to give disaccharide 21 in good yield and excellent stereoselectivity. Opening of the lactone ring using benzyl alcohol under acidic conditions¹⁹ afforded benzyl ester 22 quantitatively. Chloroacetylation of the liberated hydroxyl functionality, anomeric desilylation, and installment of the *N*-phenyltrifluoroimidate function then led to dimeric glycosyl donor 25. Coupling of this donor with lactone acceptor 5 employing TfOH as a promoter gave *S*-phenyl trimer 26 in 81% yield and 8:1 α/β selectivity, showcasing the apt nucleophilicity of lactone acceptor 5. The α-epimer of thioglycoside 26 could be isolated through column chromatography (64%) and was subsequently condensed with acceptor 9 in

a Ph₂SO/Tf₂O-mediated preactivation glycosylation event furnishing the fully protected glycerol capped trisaccharide 27 as the sole anomer. Global deprotection started with removal of the chloroacetyl group to give alcohol 28. Reduction of the azide in 28 with either PMe₃ or dithiothreitol and ensuing acetylation of the amine and free C3'-OH gave only low yields of the desired product. The use of freshly distilled thioacetic acid and pyridine on the other hand, gave acetamide 29 in 94% yield,³⁸ with the alcohol functionality still intact. Studies to open the lactone ring in compound 30 (vide infra) prompted us to use TMSO₂Na as nucleophilic reagent to hydrolyze the lactone functionality in 29.³⁹ Hydrogenolysis of the remaining benzyl ester, benzyloxy carbamate, and benzyl ethers then furnished the first target trisaccharide 1 in 52% yield over the last two steps.

For the construction of trisaccharide 2, lactone donor 4 was converted into glycerol-capped galacturonic acid ester acceptor 31 (Scheme 3). To this end, lactone donor 4 was coupled with acceptor 9 in a Ph₂SO/Tf₂O-mediated glycosylation to yield 30 with excellent anomeric selectivity (α/β = 10:1). Unfortunately, the acid-catalyzed opening of lactone 30 in benzyl alcohol as described above did not lead to the anticipated product. Instead, we observed a product resulting from the endocyclic opening of the galactopyranosyl core (32). Use of Bu₂SnO₄⁴⁰ in BnOH did give the desired product, but only in low yields. Finally, we succeeded in opening the lactone ring using TMSO₂Na to afford the free acid, which was subsequently treated with benzyl bromide and Cs₂CO₃ providing the reducing end galacturonic acid acceptor 31 in 75% yield. Next, hemiacetal 7 and key lactone acceptor 5 were coupled under the agency of Ph₂SO and Tf₂O to stereoselectively form the α-linked dimer 33 in 84% yield. The generated thioglycoside 33 was engaged next in a glycosylation event with spacer-capped galacturonic acid ester acceptor 31 to produce the fully protected trisaccharide 34, again with complete α-selectivity. To deliver target compound 2, the same global deprotection strategy was envisioned as used previously for the fully protected trisaccharide 27. Thus, dechloroacetylation with

Scheme 3^a

^a Reagents and conditions: (a) 4, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 9, 93% (α/β 10:1); (b) (1) TMSO₂Na, DCM, (2) BnBr, Cs₂CO₃, DMF, 75% (two steps); (c) 7, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 5, 84%; (d) 33, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 31, 60%; (e) thiourea, EtOH, pyridine, 65 °C, 62%; (f) thiolacetic acid/pyridine (1/1 v/v), 66%; (g) TMSO₂Na, DCM, then H₂/Pd(C), *t*-BuOH, H₂O, HCl (38%); (h) H₂/Pd(C), *t*-BuOH, H₂O, HCl, then H₂O, HCl (38%).

Scheme 4^a

^a Reagents and conditions: (a) 4, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 20, 70%; (b) (1) TMSO₂Na, DCM, (2) BnBr, Cs₂CO₃, DMF, 88% (over two steps); (c) 4, Ph₂SO, Tf₂O, DCM, TTBP, -60 °C then acceptor 39, 78%; (d) AcSH, pyridine, 40%; (e) TMSO₂Na, DCM, then H₂/Pd(C), *t*-BuOH, H₂O, HCl, 3a: 28%, 3b: 17%.

thiourea was followed by reduction of the azide group using AcSH and simultaneous N-acetylation to produce acetamide 36. Unfortunately, treatment of 36 with TMSO₂Na in dichloromethane and ensuing hydrogenolysis did not afford the anticipated trisaccharide 2. Instead, oxazolidinone 37 was obtained as a result from intramolecular nucleophilic attack of the 3''-OH onto the nearby benzyl carbamate during the TMSO₂Na treatment. The formation of the oxazolidinone could be circumvented by reversal of the lactone ring-opening and reduction steps. Hydrogenolysis of acetamide 36 under mildly acidic conditions provided the crude trimer lactone. The ¹H NMR spectrum of the crude lactone recorded directly after hydrogenolysis already showed partial hydrolysis of the lactone ring, and therefore, the crude lactone was further subjected to mild acidic hydrolysis conditions to provide the target trimer 2 in 38% over the last two steps.

The assembly of the third and last trisaccharide 3 commenced with the sulfonium bistriflate-mediated condensation of lactone

donor 4 and acceptor 20. As depicted in Scheme 4, disaccharide 38 was produced in a completely α -selective fashion in 70% yield. TMSO₂Na opening of the lactone functionality in 38 and subsequent benzyl ester installment set the stage for the next glycosylation event, in which key lactone donor 4 was employed again. The coupling of 4 and 39, proceeded without any selectivity, and trisaccharide 40 was isolated as an inseparable 1:1 mixture in 78% yield. Changing the solvent system to either toluene or acetonitrile in dichloromethane did not significantly alter the stereochemical outcome of the glycosylation. In light of the excellent α -selectivity of all previous condensations using the galacturonic acid-[3,6]-lactone donors, and especially the coupling of 33 with galacturonic acid acceptor 31, the lack of selectivity in the condensation of 4 and 39 is surprising, and we have no adequate explanation for this result at this moment. Global deprotection of the epimeric mixture was accomplished by reduction of the azide in 40 and concomitant acetylation to




Figure 3. Dionex HPAEC (high performance anion exchange chromatography) trace of the epimeric mixture obtained after hydrogenation of **41** under acidic conditions, showing a retention time difference of 12.32 min between both epimers. Recovery: 28% for **3a** and 17% for **3b** (over two steps from **41**).

give acetamide **41** in moderate yield. Then, TMSO_{Na}-mediated lactone hydrolysis and ensuing removal of the remaining protective groups left us with a crude epimeric mixture of fully deprotected trisaccharides. The two anomers could be separated by high performance anion exchange chromatography (HPAEC).⁴¹ The use of a gradient of 30–80 mM NaOAc in 100 mM NaOH led to the elution of the α - and β -epimers with a retention time difference of over 10 min, as depicted in Figure 3. Preparative ion-exchange chromatography gave us target C-1''- α -configured trisaccharide **3a** (28% over the last two steps) and its β -epimer **3b** (17% over the last two steps) in pure form. The structures of the trisaccharides were corroborated by NMR spectroscopy. The heteronuclear one-bond coupling constant of C-1'' and H-1'' in **3a** ($^1J_{C-H} = 170.3$ Hz) and **3b** ($^1J_{C-H} = 161.5$ Hz) unambiguously confirmed the α -anomeric configuration for the former and the β -anomeric configuration for the latter trisaccharide.

CONCLUSION

In summary, we have described the synthesis of all three frame-shifted trisaccharide repeats of the zwitterionic polysaccharide Sp1 of *S. pneumonia* exploiting the use of 1-thio galacturonic acid lactones as key donor and acceptor building blocks. The galacturonic acid-[3,6]-lactones proved to be efficient donor galactosides for the construction of the galacturonic acid-containing target compounds. The yields of the glycosylations using the lactone donors were good to excellent and in all but one of the galacturonylations very high α -selectivities were observed. For the unexpected lack of α -selectivity in the condensation of key lactone donor **4** and dimer acceptor **39** there currently is no satisfactory explanation. In addition to being adequate donor glycosides, the galacturonic acid lactones were also shown to be excellent nucleophiles when equipped with a free C4-hydroxyl function. The 1C_4 -chair conformation of lactone **5** places the C4-hydroxyl in an equatorial position which makes it significantly more reactive toward incoming electrophiles. It is envisaged that this strategy can also be applied to other glycuronic acid acceptors. Finally, HPAEC proved to be a powerful purification technique for this class of compounds as the difference in one stereochemical center led to a significant difference in retention time, allowing the separation of the two epimers.

EXPERIMENTAL SECTION

General Procedure for Glycosylations Using Ph₂SO/Tf₂O.

A solution of donor (1 equiv), diphenyl sulfoxide (1.1 equiv), and tri-*tert*-butylpyrimidine (1.5 equiv) in DCM (0.05M) was stirred over activated molecular sieves (3 Å) for 30 min. The mixture was cooled to -60 °C before triflic acid anhydride (1.1 equiv) was added. The mixture was allowed to warm to -45 °C and was subsequently recooled to -60 °C before a mixture (dried over 3 Å molecular sieves) of acceptor (1.5 equiv) and tri-*tert*-butylpyrimidine (1.0 equiv) in a small amount of DCM was added. Stirring was continued, and the reaction mixture was allowed to warm to -10 °C. The reaction mixture was quenched with triethylamine (5.0 equiv), diluted with DCM, and washed with satd aq NaHCO₃. The aqueous phase was extracted with DCM, and the combined organic phases were dried (MgSO₄), filtered, and concentrated under reduced pressure. Flash column chromatography and removal of the eluent afforded the coupled product.

Phenyl 2,4-Di-O-benzyl-1-thio- β -D-galactopyranoside (**13**).

To a mixture of 10.0 g of phenyl-1-thiogalactopyranoside in 150 mL of DMF (36.8 mmol, 1 equiv) was added 8.77 g of imidazole (128.8 mmol, 3.5 equiv) and 16.64 g of TBSCl (110.4 mmol, 3 equiv). After 2 h of stirring, TLC analysis showed complete consumption of the starting material. The reaction was quenched by the addition of 3 mL of MeOH. The mixture was partitioned between H₂O and Et₂O, and the aqueous layer was extracted. The combined organic phases were washed with aq 1 M HCl, satd aq NaHCO₃, and brine, dried over MgSO₄, filtered, and evaporated. The crude product was dissolved in 150 mL of DMF, and to this solution were added 13.2 mL of BnBr (110.4 mmol, 3 equiv) and 4.42 g of NaH (60% in mineral oil, 110.4 mmol, 3 equiv) at 0 °C. After being stirred at ambient temperature overnight, the reaction was quenched with MeOH at 0 °C, taken up in Et₂O, and washed with 5% aq LiCl and brine. After drying over MgSO₄, filtration, and concentration under reduced pressure, the residue was dissolved in 40 mL of THF and treated with 146.8 mL of 1.0 M TBAF (in THF, 146.8 mmol, 4 equiv). The mixture was stirred for 3 h and subsequently taken up in EtOAc and H₂O. The water layer was further extracted with EtOAc, and the combined organic layers were dried (MgSO₄), filtered, and evaporated. Purification by flash column chromatography using EtOAc/PE (7/13 \rightarrow 9/11) afforded the target compound **13** (13.4 g, 29.6 mmol, 80% over three steps): R_f 0.27 (EtOAc/PE, 1/1, v/v); $[\alpha]_D^{22} +1$ (c 1.4, CHCl₃); IR (neat, cm⁻¹) 1311, 1049, 1018, 871, 732, 640, 694; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.53 (m, 2H, H_{arom}), 7.43–7.09 (m, 13H, H_{arom}), 4.90 (d, $J = 10.8$ Hz, 1H, CH₂ Bn), 4.76 (d, $J = 11.6$ Hz, 1H, CH₂ Bn), 4.68–4.54 (m, 3H, CH₂ Bn, H-1), 3.84 (dd, $J = 11.0, 7.4$ Hz, 1H, H-6), 3.75 (s, 1H, H-4), 3.74–3.65 (m, 2H, H-2, H-3), 3.56 (dd, $J = 11.2, 4.5$ Hz, 1H, H-6), 3.49–3.42 (m, 1H, H-5), 2.41 (bs, 1H, OH), 2.03 (bs, 1H, OH); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 138.0, 137.9, 133.9 (C_q Ph), 131.2, 128.9, 128.5, 128.4, 128.3, 128.0, 127.9, 127.2 (CH_{arom}), 87.1 (C-1), 79.0 (C-5), 78.1 (C-2), 75.8, 75.7 (C-3, C-4), 75.2, 74.7 (CH₂ Bn), 62.1 (C-6); HRMS [$M + Na$]⁺ calcd for C₂₆H₂₈N₃O₅SNa 475.15497, found 475.15567.

Phenyl 2,4-Di-O-benzyl-1-thio- β -D-galactopyranosiduron-3,6-lactone (4**).** The thioglycoside lactone was synthesized as reported previously, and all physical and spectroscopic data were in accordance with the published data.²⁵ Previously, assignments of H-4 and H-5 as well as C-4 and C-5 were interchanged. See ref 25. ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.63–7.09 (m, 15H, H_{arom}), 5.41 (s, 1H, H-1), 4.80 (dd, $J = 4.7, 1.3$ Hz, 1H, H-3), 4.65 (d, $J = 11.8$ Hz, 1H, CH₂ Bn), 4.59 (2s, 2H, CH₂ Bn), 4.54 (d, $J = 11.8$ Hz, 1H, CH₂ Bn), 4.39 (br s, 1H, H-4), 4.27 (d, $J = 4.7$ Hz, 1H, H-2), 4.04 (br s, 1H, H-5); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC): δ 172.6 (C=O), 136.7, 136.5, 133.6 (C_q Ph), 132.7, 129.0, 128.7, 128.6, 128.5, 128.3, 128.1, 128.0, 127.8 (CH_{arom}), 85.8 (C-1), 78.9 (C-3), 78.6 (C-2), 76.0 (C-4), 73.0 (CH₂ Bn), 71.5 (CH₂ Bn), 70.8 (C-5).

Phenyl 2-O-Benzyl-1-thio- β -D-galactopyranosiduron-3,6-lactone (5**).** To a vigorously stirred solution of 3.59 g of

phenyl 2-*O*-benzyl-3,4-*O*-isopropylidene-1-thio- β -galactopyranoside (8.93 mmol, 1 equiv) in 30 mL of DCM and 15 mL of H₂O was added 279 mg of TEMPO (1.79 mmol, 0.2 equiv) and 7.19 g of BAIB (22.3 mmol, 2.5 equiv). After 2 h of stirring at room temperature, Na₂S₂O₃ solution (10% in H₂O) was added, and the mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried (MgSO₄), filtered, and evaporated. The crude acid was stirred at 65 °C in 20 mL of AcOH/H₂O (4/1 v/v) until TLC analysis showed disappearance of the starting material. The mixture was concentrated in vacuo and coevaporated with toluene. The crude product was dissolved in 350 mL of anhydrous DCM followed by addition of 1.77 mL of DiPEA (10.7 mmol, 1.2 equiv) and 939 μ L of ethyl chloroformate (9.82 mmol, 1.1 equiv). After 3 h of stirring at ambient temperature, the mixture was evaporated, and lactone **5** was obtained in pure form after flash column chromatography using EtOAc/PE (1/4 \rightarrow 1/3) (1.08 g, 3.0 mmol, 34% over three steps): *R*_f 0.26 (EtOAc/PE, 3/7, v/v); [α]²²_D -223 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 3440, 1794, 1095, 1055, 694; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.45–7.23 (m, 10H, H_{arom}), 5.39 (s, 1H, H-1), 4.77 (dd, *J* = 4.7, 1.3 Hz, 1H, H-3), 4.62–4.50 (m, 3H, H-4, CH₂ Bn), 4.22 (d, *J* = 4.7 Hz, 1H, H-2), 3.98 (t, *J* = 1.3 Hz, 1H, H-5), 3.29 (s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 174.1 (C=O), 136.4, 133.4 (C_q Ph), 132.5, 129.0, 128.6, 128.3, 128.1, 128.0 (CH_{arom}), 85.3 (C-1), 81.2 (C-3), 78.3 (C-2), 72.9 (CH₂ Bn), 72.5 (C-5), 69.5 (C-4); HRMS [M + Na]⁺ calcd for C₁₉H₁₈O₅SNa 381.07672, found 381.07675. When lactonization of the crude acid diol **16** was executed at a 0.21 M concentration, lactone **5** was isolated in 26% along with 19% of 2-*O*-benzyl-1-thio- β -D-galactopyranosyluronate (17): *R*_f 0.41 (EtOAc/PE, 2/3, v/v); [α]²²_D -158 (c 2.0, CH₂Cl₂); IR (neat, cm⁻¹) 3470, 1806, 1774, 1101, 741, 692; “a” designates signals belonging to the galacturonic acid ester, and “b” is used for signals stemming from the galacturonic acid lactone; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 7.0 Hz, 2H, H_{arom}), 7.48–7.20 (m, 18H, H_{arom}), 5.59 (s, 1H, H-4b), 5.44 (s, 1H, H-1b), 5.08 (d, *J* = 4.6 Hz, 1H, H-3b), 4.93 (d, *J* = 10.8 Hz, 1H, CH₂ Bn), 4.70–4.65 (m, 2H, CH₂ Bn), 4.62–4.54 (m, 2H, CH₂ Bn, H-1a), 4.35 (d, *J* = 4.8 Hz, 1H, H-2b), 4.20–4.16 (m, 2H, H-4a, H-5b), 4.09 (s, 1H, H-5a), 3.73–3.62 (m, 2H, H-3a, H-2a), 3.50 (d, *J* = 4.1 Hz, 1H, OH), 3.25 (d, *J* = 4.1 Hz, 1H, OH); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) ¹³C NMR (101 MHz, CDCl₃) δ 171.9, 166.3 (C=O), 137.9, 136.3, 133.3 (C_q Ph), 133.0, 132.6, 132.4, 129.0, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.9 (CH_{arom}), 87.6 (C-1a), 86.3 (C-1b), 78.4 (C-3b), 78.1 (C-2b), 77.2 (C-2a), 76.4 (C-5a), 75.4 (CH₂ Bn), 74.0 (C-3a), 72.9 (CH₂ Bn), 72.6 (C-4b), 70.0, 69.8 (C-4a, C-5b); HRMS [M + Na]⁺ calcd for C₃₈H₃₆O₁₀S₂Na 739.16421, found 739.16431.

tert-Butyldiphenylsilyl 4-(*N*-benzyloxycarbonylamino)-2-azido-3-*O*-chloroacetyl-2,4,6-trideoxy- β -D-galactopyranoside (18). To a mixture of alcohol **6** (860 mg, 1.54 mmol, 1 equiv), 5 mL of DCM, and 607 μ L of pyridine (7.68 mmol, 5 equiv) was added 525 mg of chloroacetic anhydride (3.07 mmol, 2 equiv). After 1 h, 500 μ L of H₂O was added, and the mixture was stirred for another 15 min. After evaporation, the residue was taken up in EtOAc and washed with aq 1 M HCl, satd aq NaHCO₃, and brine. The organic phase was dried over MgSO₄, filtered, and evaporated to dryness yielding title compound **18** (984 mg, 1.54 mmol, quant): *R*_f 0.79 (EtOAc/PE, 1/3, v/v); [α]²²_D -9 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2114, 1713, 1504, 1165, 1057, 733; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.71–7.68 (m, 4H, H_{arom}), 7.46–7.25 (m, 11H, H_{arom}), 5.14 (d, *J* = 12.2 Hz, 1H, CH₂ Cbz), 5.02 (d, *J* = 12.2 Hz, 1H, CH₂ Cbz), 4.93 (d, *J* = 9.5 Hz, 1H, NH), 4.64 (dd, *J* = 10.7, 3.7 Hz, 1H, H-3), 4.44 (d, *J* = 7.7 Hz, 1H, H-1), 4.00 (dd, *J* = 9.5, 3.4 Hz, 1H, H-4), 3.95–3.81 (m, 2H, CH₂, ClAc), 3.48 (dd, *J* = 10.4, 8.0 Hz, 1H, H-2), 3.36 (q, *J* = 6.2 Hz, 1H, H-5), 1.11 (s, 9H, CH₃

t-Bu), 0.97 (d, *J* = 6.3 Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 166.5, 156.45 (C=O), 136.2 (C_q Ph), 135.7 (CH_{arom}), 132.9, 132.4 (C_q Ph), 129.9, 128.5, 128.3, 128.1, 127.5, 127.4 (CH_{arom}), 97.0 (C-1), 74.6 (C-3), 68.9 (C-5), 67.1 (CH₂ Cbz), 63.5 (C-2), 51.6 (C-4), 40.5 (CH₂ ClAc), 26.7 (CH₃ *t*-Bu), 19.0, (C_q *t*-Bu), 16.0 (C-6); HRMS [M + Na]⁺ calcd for C₃₂H₃₇ClN₄O₆·SiNa 659.20631, found 659.20672.

4-(*N*-benzyloxycarbonylamino)-2-azido-3-*O*-chloroacetyl-2,4,6-trideoxy-D-galactopyranose (7). Galactosazide **18** (1.03 g, 1.62 mmol, 1 equiv) in 10 mL of THF was treated with 527 μ L of N₃Et·3HF (3.23 mmol, 2 equiv), and the mixture was stirred at 70 °C for 30 min. When the reaction mixture had cooled to ambient temperature, EtOAc was added, and the organic mixture was washed with satd aq NaHCO₃. The aqueous layer was extracted with DCM, and the combined organic layers were dried over MgSO₄, filtered, and evaporated. Purification by flash column chromatography using EtOAc/PE (1/3 \rightarrow 3/7) yielded galactopyranose **7** (632 mg, 1.58 mmol, 98%, α/β 1:2) with a minor unidentified side product: *R*_f 0.42 (EtOAc/PE, 2/3, v/v); IR (neat, cm⁻¹) 3356 (br), 2361, 2114, 1701, 1526, 1061; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.42–7.29 (m, 5H, H_{arom}), 5.44 (d, *J* = 9.6 Hz, 0.7H, NH- α), 5.35–5.28 (m, 0.6H, H-1 α , H-3 α), 5.17–5.04 (m, 2H, CH₂ Cbz- α , CH₂ Cbz- β), 4.75 (dt, *J* = 13.2, 6.6 Hz, 0.7H, H-3 β), 4.63 (d, *J* = 8.0 Hz, 0.7H, H-1 β), 4.52–4.47 (m, 0.3H, H-5 α), 4.33 (s, 0.7H, OH- β), 4.26–4.22 (m, 0.3H, H-4 α), 4.18–4.12 (m, 0.7H, H-4 β), 3.96–3.86 (m, 2H, CH₂ ClAc), 3.81–3.74 (m, 0.7H, H-5 β), 3.56 (dd, *J* = 11.1, 3.7 Hz, 0.3H, H-2 α), 3.50 (dd, *J* = 10.8, 8.0 Hz, 0.7H, H-2 β), 3.42 (s, 0.3H, OH- α), 1.24 (d, *J* = 6.4 Hz, 0.7H, H-6 β), 1.18 (d, *J* = 6.5 Hz, 0.3H, H-6 α); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 166.9, 157.1, 157.0 (C=O), 136.1, 136.0 (C_q Ph), 128.6, 128.5, 128.3, 128.1, 127.9 (CH_{arom}), 96.2 (C-1 β), 91.8 (C-1 α), 74.6 (C-3 β), 72.2 (C-3 α), 69.2 (C-5 β), 67.3, 67.2 (CH₂ Cbz), 64.1 (C-5 α), 61.8 (C-2 β), 58.0 (C-2 α), 52.5 (C-4 α), 51.8 (C-4 β), 40.6, 40.5 (CH₂ ClAc), 16.4 (C-6 β), 16.3 (C-6 α); HRMS [M + H]⁺ calcd for C₁₆H₂₀ClN₄O₆ 399.10659, found 399.10647.

4-(*N*-benzyloxycarbonylamino)-2-azido-3-*O*-chloroacetyl-2,4,6-trideoxy- α/β -D-galactopyranosyl (*N*-Phenyl)trifluoroacetimidate (8). To a solution of 511 mg of hemiacetal **7** (1.28 mmol, 1 equiv) in 6.1 mL of acetone and 0.3 mL of H₂O were added 460 mg of CsCO₃ (1.41 mmol, 1.1 equiv) and 532 mg of ClC(C=NPh)CF₃ (2.56 mmol, 2 equiv). When TLC analysis showed complete consumption of the starting material, the mixture was coevaporated with toluene. Purification by flash column chromatography using EtOAc/PE (1/9 \rightarrow 3/7) yielded 606 mg of imidate **8** (1.06 mmol, 83%, anomers α/β 1:3): *R*_f 0.54 (EtOAc/PE, 1/3, v/v); IR (neat, cm⁻¹) 2116, 1717, 1524, 1211, 1163, 1072, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) (*T* = 333 K) δ 7.41–7.23 (m, 9.3H, H_{arom}), 7.09 (m, 1.4H, H_{arom}), 6.83 (m, 2.7H, H_{arom}), 6.35 (s, 0.3H, H-1 α), 5.49 (d, *J* = 7.5 Hz, 1H, H-1 β), 5.28 (dd, *J* = 11.1, 3.5 Hz, 0.3H, H-3 α), 5.20–4.96 (m, 4H, CH₂ Cbz, NH), 4.81 (dd, *J* = 10.7, 3.9 Hz, 1H, H-3 β), 4.38–4.26 (m, 0.7H, H-4 α , H-5 α), 4.16 (dd, *J* = 9.7, 3.1 Hz, 1H, H-4 β), 3.89 (s, 2.7H, CH₂ ClAc), 3.81 (dd, *J* = 10.9, 3.9 Hz, 0.3H, H-2 α), 3.75–3.59 (m, 2H, H-2 β , H-5 β), 1.20 (m, 4H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) (*T* = 333K) δ 166.4, 156.7 (C=O), 143.1, 143.0, 136.3 (C_q Ph), 128.8, 128.6, 128.3, 128.0, 124.7, 124.6, 119.3, 119.2 (CH_{arom}), 95.9 (C-1 β), 93.7 (C-1 α), 74.6 (C-3 β), 72.2 (C-3 α), 70.6 (C-5 β), 67.5 (C-5 α), 67.4 (CH₂ Cbz), 60.2 (C-2 β), 57.2 (C-2 α), 52.4 (C-4 α), 51.8 (C-4 β), 40.3 (CH₂ ClAc), 16.2 (C-6); HRMS [M - (C(N=Ph)CF₃) + H + Na]⁺ calcd for C₁₆H₁₉ClN₄O₆ 421.08853, found 421.08845.

4-(*N*-benzyloxycarbonylamino)-2-azido-3-*O*-chloroacetyl-2,4,6-trideoxy- α/β -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-*O*-benzyl-*sn*-glycerol (19). A catalytic amount of triflic acid was added under anhydrous conditions to a mixture of 403 mg of imidate **8** (707 μ mol, 1 equiv) and 578 mg of alcohol **9** (2.21 mmol, 3 equiv) in 7 mL of DCM/Et₂O (1/1 v/v) at 0 °C. After 20 min of stirring, TLC analysis

showed complete conversion of the starting material. The reaction was quenched by adding triethylamine, and the solvents were removed in vacuo. Purification by size-exclusion chromatography (DCM/MeOH 1/1 v/v) yielded the title compound as an anomeric mixture (460 mg, 704 μmol , α/β 4:1, quant): R_f 0.81 (EtOAc/PE, 3/7, v/v); IR (neat, cm^{-1}) 2936, 2111, 1768, 1718, 1520, 1041, 698; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.42–7.23 (m, 18.8H, H_{arom}), 5.25 (dd, $J = 11.1$, 3.7 Hz, 1H, H-3 α), 5.13 (dd, $J = 10.6$, 7.5 Hz, 2.5H, CH_2 Cbz, NH), 5.01 (d, $J = 12.3$ Hz, 1.25H, CH_2 Cbz), 4.89 (d, $J = 3.7$ Hz, 1H, H-1 α), 4.72–4.60 (m, 2.8H, CH_2 Bn, H-3 β), 4.58–4.48 (m, 2.5H, CH_2 Bn), 4.28 (d, $J = 8.0$ Hz, 0.25H, H-1 β), 4.18–4.04 (m, 2.25H, H-4 α , H-5 α , H-4 β), 3.99–3.73 (m, 4.8H, CH_2 Gro, CH Gro, CH_2 ClAc), 3.63–3.57 (m, 4H, CH_2 Gro, H-5 β), 3.45–3.35 (m, 1.3H, H-2 β , H-2 α), 1.19 (d, $J = 6.3$ Hz, 0.8H, H-6 β), 1.04 (d, $J = 6.4$ Hz, 3H, H-6 α); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 166.6, 156.6, 156.5 (C=O), 138.2, 137.9, 136.2 (C_q Ph), 128.5, 128.3, 128.2, 127.9, 127.6, 127.5 (CH_{arom}), 102.2 (C-1 β), 97.9 (C-1 α), 76.8 (CH Gro- β), 76.6 (CH Gro- α), 74.3 (C-3 β), 73.3 (C-2 β), 72.1, 72.0 (CH_2 Bn), 71.6 (C-3 α), 69.5, 69.4, 69.2 (CH_2 Gro), 68.9 (C-5 β), 67.9 (CH_2 Gro), 67.0 (CH_2 Cbz), 64.0 (C-5 α), 60.8 (C-2 β), 57.2 (C-2 α), 52.3 (C-4 α), 51.6 (C-4 β), 40.5 (CH_2 ClAc), 16.3 (C-6 β), 16.1 (C-6 α); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{33}\text{H}_{37}\text{ClN}_4\text{O}_8\text{Na}$ 675.21921, found 675.21973.

4-(*N*-Benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-*O*-benzyl-*sn*-glycerol (20 α) and 4-(*N*-Benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- β -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-*O*-benzyl-*sn*-glycerol (20 β). A mixture of 460 mg of azide **19** (704 μmol , 1 equiv), 454 μL of pyridine (5.63 mmol, 8 equiv), 161 mg of thiourea (2.11 mmol, 3 equiv), and 7 mL of ethanol was stirred for 3 h at 65 $^\circ\text{C}$. The mixture was concentrated, and the crude residue was taken up in EtOAc. The organic phase was washed with aq 1 M HCl, satd aq NaHCO_3 , and brine, dried over MgSO_4 , filtered, and evaporated. Purification by flash column chromatography using EtOAc/PE (1/4 \rightarrow 3/7) yielded 317 mg of **20 α** (549 μmol , 78%) and 66 mg of **20 β** (114 μmol , 16%). **20 α** : R_f 0.3 (EtOAc/PE, 1/3, v/v); $[\alpha]_D^{25} +91$ (c 1.0, CH_2Cl_2); IR (neat, cm^{-1}) 3418, 2916, 2106, 1697, 1026, 725; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.40–7.23 (m, 15H, H_{arom}), 5.17–5.06 (m, 3H, NH, CH_2 Cbz), 4.81 (d, $J = 3.7$ Hz, 1H, H-1), 4.71–4.62 (m, 2H, CH_2 Bn), 4.54 (dd, $J = 12.0$, 12.0 Hz, 2H, CH_2 Bn), 4.14 (dd, $J = 10.7$, 3.5 Hz, 1H, H-3), 4.08 (q, $J = 6.5$ Hz, 1H, H-5), 3.96 (dd, $J = 8.8$, 2.5 Hz, 1H, H-4), 3.83–3.76 (m, 2H, CH Gro, CH_2 Gro), 3.63 (d, $J = 4.7$ Hz, 2H, CH_2 Gro), 3.57 (dd, $J = 9.4$, 4.3 Hz, 1H, CH_2 Gro), 3.24 (s, 1H, OH), 3.12 (dd, $J = 10.7$, 3.6 Hz, 1H, H-2), 1.07 (d, $J = 6.5$ Hz, 3H, H-6); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 158.1 (C=O), 138.3, 138.0, 135.8 (C_q Ph), 128.6, 128.3, 128.1, 127.7, 127.6, 127.6 (CH_{arom}), 98.2 (C-1), 76.8 (CH Gro), 73.4 (CH_2 Bn), 72.1 (CH_2 Bn), 69.4 (CH_2 Gro), 68.5 (C-3), 67.6 (CH_2 Gro), 67.5 (CH_2 Cbz), 64.5 (C-5), 60.4 (C-2), 55.8 (C-4), 16.4 (C-6); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{31}\text{H}_{36}\text{N}_4\text{O}_7\text{Na}$ 599.24762, found 599.24731. **20 β** : R_f 0.16 (EtOAc/PE, 1/3, v/v); $[\alpha]_D^{25} -13$ (c 1.0, CH_2Cl_2); IR (neat, cm^{-1}) 3348, 2870, 2106, 1705, 1049, 741; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.47–7.17 (m, 15H, H_{arom}), 5.29–5.03 (m, 3H, NH, CH_2 Cbz), 4.67 (s, 2H, CH_2 Bn), 4.54 (s, 2H, CH_2 Bn), 4.22 (d, $J = 8.0$ Hz, 1H, H-1), 3.99–3.91 (m, 2H, CH_2 Gro, H-4), 3.83–3.78 (m, 1H, CH Gro), 3.72 (dd, $J = 10.2$, 5.2 Hz, 1H, CH_2 Gro), 3.63 (dd, $J = 4.9$, 1.5 Hz, 2H, CH_2 Gro), 3.60–3.53 (m, 2H, H-3, H-5), 3.22 (dd, $J = 10.0$, 8.2 Hz, 1H, H-2), 3.16 (d, $J = 2.3$ Hz, 1H, OH), 1.19 (d, $J = 6.2$ Hz, 3H, H-6); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 158.0 (C=O), 138.6, 138.2, 136.0 (C_q Ph), 128.6, -128.4, 128.3, 128.1, 127.7, 127.6 (CH_{arom}), 102.5 (C-1), 77.0 (CH Gro), 73.5 (CH_2 Bn), 72.5 (C-3), 72.3 (CH_2 Bn), 69.8 (CH_2 Gro), 69.5 (C-5) (CH_2 Gro), 67.5 (CH_2 Cbz), 64.5 (C-2), 54.9 (C-4), 16.6 (C-6); HRMS [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{31}\text{H}_{36}\text{N}_4\text{O}_7$ 577.26568, found 577.26583.

2,4-Di-*O*-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-*tert*-butyldiphenylsilyl 4-(*N*-Benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- β -D-galactopyranoside (21).

Lactone **4** (338 mg) was coupled to alcohol **6** (0.77 equiv instead of 1.5 equiv) according to the general procedure for glycosidations using $\text{Ph}_2\text{SO}/\text{Ti}_2\text{O}$. The reaction was quenched using triethylamine (5 equiv), and the title compound **21** was obtained in 75% yield (391 mg, 435 μmol): flash column chromatography eluent: EtOAc/toluene (0/1 \rightarrow 1/49); R_f 0.78 (EtOAc/toluene, 1/4, v/v); $[\alpha]_D^{25} 27$ (c 1.0, CH_2Cl_2); IR (neat, cm^{-1}) 2860, 2361, 2114, 1800, 1717, 1506, 1061; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.79–7.08 (m, 25H, H_{arom}), 5.13–5.00 (m, 3H, CH_2 Cbz, H-1'), 4.92 (d, $J = 9.7$ Hz, 1H, NH), 4.79 (d, $J = 11.6$ Hz, 1H, CH_2 Bn), 4.71 (d, $J = 3.8$ Hz, 1H, H-3'), 4.62–4.52 (m, 2H, CH_2 Bn), 4.50 (s, 1H, H-4'), 4.36 (d, $J = 7.8$ Hz, 1H, H-1), 4.27 (d, $J = 11.6$ Hz, 1H, CH_2 Bn), 4.18 (s, 1H, H-5'), 4.05 (dd, $J = 4.9$, 2.1 Hz, 1H, H-2'), 3.92 (dd, $J = 10.0$, 3.7 Hz, 1H, H-4), 3.68 (dd, $J = 10.5$, 4.0 Hz, 1H, H-3), 3.30–3.23 (m, 2H, H-2, H-5), 1.10 (s, 9H, CH_3 *t*-Bu), 1.00 (d, $J = 6.3$ Hz, 3H, H-6); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 171.8 (C=O), 156.5 (C=O Cbz), 138.0, 136.8 (C_q Ph), 135.8 (CH_{arom}), 133.1, 132.5 (C_q Ph), 129.9, 129.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.8, 127.7, 127.5, 127.4 (CH_{arom}), 96.9 (C-1), 95.6 (C-1'), 80.4 (C-3'), 77.1 (C-3), 75.8 (C-4'), 75.0 (C-2'), 74.3 (CH_2 Bn), 72.2 (C-5'), 71.5 (CH_2 Bn), 69.0 (C-5), 67.2 (CH_2 Cbz), 64.8 (C-2), 50.9 (C-4), 26.8 (CH_3 *t*-Bu), 19.1 (C_q *t*-Bu), 16.3 (C-6); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{50}\text{H}_{54}\text{N}_4\text{O}_{10}\text{SiNa}$ 921.35014, found 921.35091.

Benzyl 2,4-Di-*O*-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-*tert*-butyldiphenylsilyl 4-(*N*-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- β -D-galactopyranoside (22). After addition of a catalytic amount of AcCl to a solution of 412 mg of lactone **21** (367 μmol) in 2 mL of BnOH, the mixture was allowed to stir overnight at 50 $^\circ\text{C}$. Following neutralization using triethylamine, the mixture was diluted with EtOAc and washed with satd aq NaHCO_3 and brine. The organic phase was dried (MgSO_4), filtered, and concentrated in vacuo. Size-exclusion chromatography (DCM/MeOH 1/1 v/v) followed by flash column chromatography using EtOAc/toluene (1/19 \rightarrow 1/9) gave 370 mg (367 μmol , quant) of the title compound **22**: R_f 0.51 (EtOAc/toluene, 1/4, v/v); $[\alpha]_D^{25} +34$ (c 0.39, CH_2Cl_2); IR (neat, cm^{-1}) 3500, 2932, 2112, 1761, 1719, 1508, 1107, 1059; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.75–7.60 (m, 4H, H_{arom}), 7.49–7.16 (m, 24H, H_{arom}), 7.14–7.03 (m, 2H, H_{arom}), 5.54 (d, $J = 3.3$ Hz, 1H, H-1'), 5.14 (d, $J = 12.2$ Hz, 1H, CH_2 Bn), 5.06 (m, 2H, CH_2 Bn), 4.91 (d, $J = 10.4$ Hz, 1H, NH), 4.76 (d, $J = 12.2$ Hz, 1H, CH_2 Bn), 4.68–4.61 (m, 3H, H-5', CH_2 Bn), 4.42–4.36 (m, 3H, H-1, CH_2 Bn), 4.30 (s, 1H, H-4'), 4.21 (dd, $J = 10.0$, 3.2 Hz, 1H, H-3'), 4.09 (dd, $J = 10.1$, 3.5 Hz, 1H, H-4), 3.90 (dd, $J = 10.1$, 3.3 Hz, 1H, H-2'), 3.57 (dd, $J = 10.8$, 4.2 Hz, 1H, H-3), 3.38 (dd, $J = 10.9$, 7.7 Hz, 1H, H-2), 3.23 (q, $J = 6.1$ Hz, 1H, H-5), 2.12 (s, 1H, OH), 1.09 (s, 9H, CH_3 *t*-Bu), 0.92 (d, $J = 6.3$ Hz, 3H, H-6); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 168.3 (C=O), 156.7 (C=O Cbz), 138.2, 137.8, 136.0 (C_q Ph), 135.8, 135.7 (CH_{arom}), 135.1, 133.2, 132.8 (C_q Ph), 129.9, 129.8, 128.5, 128.4, 128.2, 128.0, 127.9, 127.6, 127.5, 127.4 (CH_{arom}), 97.2 (C-1), 92.1 (C-1'), 77.6 (C-4'), 74.9 (CH_2 Bn), 74.8 (C-2'), 72.3 (C-3), 72.0 (CH_2 Bn), 70.6 (C-5'), 69.8 (C-5), 69.3 (C-3'), 67.0 (CH_2 Cbz, CH_2 Bn), 65.3 (C-2), 49.9 (C-4), 26.8 (CH_3 *t*-Bu), 19.1 (C_q *t*-Bu), 16.0 (C-6); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{57}\text{H}_{62}\text{N}_4\text{O}_{11}\text{SiNa}$ 1029.40766, found 1029.40828.

Benzyl 2,4-Di-*O*-benzyl-3-*O*-chloroacetyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-*tert*-butyldiphenylsilyl 4-(*N*-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- β -D-galactopyranoside (23). Alcohol **22** (2.10 g, 2.09 mmol, 1 equiv) was coevaporated with toluene and dissolved in 10 mL of DCM. A 1.68 mL (20.9 mmol, 10 equiv) portion of pyridine and 1.07 g of (ClAc) $_2\text{O}$ (6.3 mmol, 3 equiv) were added at 0 $^\circ\text{C}$, and the mixture was stirred at ambient temperature for 2.5 h. Next, H_2O and EtOAc were added, and the organic phase was washed with aq 1 M HCl, satd aq NaHCO_3 and brine.

The organic layer was dried (MgSO₄), filtered, and evaporated. Purification by flash column chromatography using EtOAc/Tol (0/1 → 1/19) yielded 2.11 g of chloroacetate **23** (1.94 mmol, 93%): *R*_f 0.81 (EtOAc/toluene, 1/4, v/v); [α]_D²² +78 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2936, 2112, 1760, 1718, 1508, 1063, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.68 (dd, *J* = 7.0, 3.4 Hz, 4H, H_{arom}), 7.46–7.12 (m, 24H, H_{arom}), 7.08–6.97 (m, 2H, H_{arom}), 5.53 (d, *J* = 3.3 Hz, 1H, H-1'), 5.41 (dd, *J* = 10.5, 2.9 Hz, 1H, 3'), 5.15 (dd, *J* = 12.1, 12.1 Hz, 2H, CH₂ Bn), 5.03 (d, *J* = 12.2 Hz, 1H, CH₂ Bn), 4.89 (d, *J* = 10.4 Hz, 1H, NH), 4.78 (s, 1H, S'), 4.67 (dd, *J* = 12.4, 12.4 Hz, 2H, CH₂ Bn), 4.44–4.37 (m, 3H, H-4', H-1, CH₂ Bn), 4.31 (dd, *J* = 11.8, 11.8 Hz, 2H, CH₂ Bn), 4.14–4.02 (m, 2H, H-2', H-4), 3.63 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 3.58 (dd, *J* = 10.8, 4.1 Hz, 1H, H-3), 3.51 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 3.42 (dd, *J* = 10.7, 7.7 Hz, 1H, H-2), 3.23 (q, *J* = 6.1 Hz, 1H, H-5), 1.10 (s, 9H, CH₃ *t*-Bu), 0.91 (d, *J* = 6.3 Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 167.8, 166.4 (C=O), 156.6 (C=O Cbz), 138.0, 137.7, 136.0 (C_q Ph), 135.8, 135.7 (CH_{arom}), 134.9, 133.2, 132.8 (C_q Ph), 129.9, 129.8, 128.8, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4 (CH_{arom}), 97.3 (C-1), 92.7 (C-1'), 76.8 (C-4'), 75.0 (CH₂ Bn), 72.9 (C-3'), 72.6 (C-3, CH₂ Bn), 72.2 (C-2'), 70.2 (C-5'), 69.7 (C-5), 67.2, 66.9 (CH₂ Bn), 65.1 (C-2), 49.9 (C-4), 40.3 (CH₂ ClAc), 26.8 (CH₃ *t*-Bu), 19.1 (C_q *t*-Bu), 16.0 (C-6); HRMS [M + Na]⁺ calcd for C₅₉H₆₃ClN₄O₁₂SiNa 1105.37925, found 1105.38018.

Benzyl 2,4-Di-O-benzyl-3-O-chloroacetyl-α-D-galactopyranosyluronate-(1→3)-4-(N-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy-D-galactopyranose (24). A mixture of 2.05 g of dimer **23** (1.89 mmol, 1 equiv), 20 mL of THF and 2.47 mL of triethylamine·3HF (15.13 mmol, 8 equiv) was stirred overnight at 70 °C. The solvent was removed using a rotary evaporator, and the crude anomers were purified by flash column chromatography using EtOAc/PE (7/13→9/11). The title compound **24** (1.35 g, 1.60 mmol, 84%, α/β 1:4) was obtained. Data of major anomer (β): *R*_f 0.24 (EtOAc/PE, 2/3, v/v); IR (neat, cm⁻¹) 3425, 2108, 1763, 1717, 1541, 1244, 1036; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.38–7.15 (m, 18H, H_{arom}), 7.08–7.00 (m, 2H, H_{arom}), 5.54 (d, *J* = 3.3 Hz, 1H, H-1'), 5.43–5.36 (m, 2H, H-3', NH), 5.21–5.10 (m, 2H, CH₂ Bn), 5.06 (d, *J* = 12.3 Hz, 1H, CH₂ Cbz or CH₂ CO₂Bn), 4.85 (s, 1H, H-5'), 4.67 (m, 2H, CH₂ Bn), 4.55 (d, *J* = 7.0 Hz, 1H, H-1), 4.44–4.37 (m, 2H, CH₂ Bn, H-4'), 4.36–4.28 (m, 2H, CH₂ Bn), 4.20 (dd, *J* = 10.4, 4.3 Hz, 1H, H-4), 4.11 (dd, *J* = 10.5, 3.3 Hz, 1H, H-2'), 3.70 (dd, *J* = 10.8, 4.2 Hz, 1H, H-3), 3.66–3.44 (m, 4H, CH₂ ClAc, H-5, H-2), 1.19 (d, *J* = 6.3 Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 167.8, 166.3 (C=O), 156.9 (C=O Cbz), 137.7, 137.6, 136.0, 134.7 (C_q Ph), 128.9, 128.7, 128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4 (CH_{arom}), 96.5 (C-1), 92.5 (C-1'), 76.7 (C-4'), 74.9 (CH₂ Cbz or CH₂ CO₂Bn), 72.8, (C-3'), 72.5 (CH₂ Cbz or CH₂ CO₂Bn), 72.4 (C-3), 72.2 (C-2'), 70.1 (C-5'), 69.8 (C-5), 67.2, 66.7 (CH₂ Bn), 63.1 (C-2), 49.9 (C-4), 40.2 (CH₂ ClAc), 16.4 (C-6); HRMS [M + Na]⁺ calcd for C₁₆H₁₉ClN₄O₆Na 867.26147, found 867.26183.

Benzyl 2,4-Di-O-benzyl-3-O-chloroacetyl-α-D-galactopyranosyluronate-(1→3)-4-(N-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy-D-galactopyranosyl N-Phenyltrifluoroacetimidate (25). To a solution of 666 mg of hemiacetal **24** (0.787 mmol, 1 equiv) in 15 mL of acetone/H₂O (19/1) were added 282 mg of Cs₂CO₃ (0.866 mmol, 1.1 equiv) and 327 mg of ClC(C=NPh)CF₃ (1.57 mmol, 2.0 equiv). The mixture was stirred overnight at ambient temperature and evaporated to dryness after the addition of 328 μL of triethylamine (2.36 mmol, 3.0 equiv). Flash column chromatography of the crude product using EtOAc/PE (3/7) with 1% triethylamine as eluent afforded 680 mg (669 μmol, 85%) of the title imidate as one of the two possible epimers: *R*_f 0.64 (EtOAc/toluene, 1/4, v/v); IR (neat, cm⁻¹) 2112, 1759, 1717, 1516, 1209, 1078, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.39–7.18 (m, 20H,

H_{arom}), 7.13 (t, *J* = 7.5 Hz, 1H, H_{arom}), 7.08–7.00 (m, 2H, H_{arom}), 6.84 (d, *J* = 7.8 Hz, 2H, H_{arom}), 5.57 (d, *J* = 2.8 Hz, 1H, H-1'), 5.41 (dd, *J* = 10.6, 2.9 Hz, 1H, H-3'), 5.23–5.03 (m, 4H, NH, CH₂ Cbz or CH₂ CO₂Bn), 4.79 (s, 1H, H-5'), 4.74–4.64 (m, 2H, CH₂ Cbz or CH₂ CO₂Bn, CH₂ Bn), 4.46–4.38 (m, 2H, CH₂ Bn, H-4'), 4.37–4.22 (m, 3H, CH₂ Bn, H-4), 4.13 (dd, *J* = 10.5, 3.4 Hz, 1H, H-2'), 3.82–3.73 (m, 1H, H-5), 3.73–3.66 (m, 1H, H-2), 3.63 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 3.52 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 1.22 (d, *J* = 6.9 Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 167.6, 166.4 (C=O), 156.6 (C=O Cbz), 142.9, 137.8, 137.6, 135.8, 134.8 (C_q Ph), 128.8, 128.8, 128.7, 128.6, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 124.6, 119.2 (CH_{arom}), 92.9 (C-1'), 76.8 (C-4'), 75.1 (CH₂ Cbz or CH₂ CO₂Bn), 72.8 (C-3'), 72.7 (CH₂ Cbz or CH₂ CO₂Bn), 72.6 (C-3 or C-5), 72.1 (C-2'), 71.2 (C-3 or C-5), 70.3 (C-5'), 67.3, 67.0 (CH₂ Bn), 61.3 (C-2), 49.7 (C-4), 40.3 (CH₂ ClAc), 16.3 (C-6); HRMS [M - (C(N=Ph)CF₃) + H + Na]⁺ calcd for C₄₃H₄₅ClN₄O₁₂Na 867.26147, found 867.26164.

Benzyl 2,4-Di-O-benzyl-3-O-chloroacetyl-α-D-galactopyranosyluronate-(1→3)-4-(N-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy-D-galactopyranosyl-(1→4)-phenyl 2-O-benzyl-1-thio-β-D-galactopyranosidurono-3,6-lactone (26).

Imidate donor (**25**) (600 mg, 590 μmol, 1 equiv) and 391 mg of lactone acceptor **5** (1.09 mmol, 1.85 equiv) were coevaporated with toluene and stirred over activated 3 Å molecular sieves in 6 mL of DCM for 30 min. The mixture was cooled to 0 °C before 5 μL of triflic acid (59 μmol, 0.1 equiv) was added. After 30 min of stirring, the reaction was quenched by the addition of 41 μL of triethylamine (295 μmol, 0.5 equiv). The mixture was diluted with DCM and washed with satd aq NaHCO₃. The aqueous phase was extracted with DCM, and the combined organic extracts were dried (MgSO₄), filtered, and concentrated under reduced pressure. Size-exclusion chromatography (DCM/MeOH 1/1 v/v) gave 565 mg (476 μmol, 81%) of the two possible epimers. Partial separation of this mixture by flash column chromatography (eluent: EtOAc/PE 1/3 → 9/11) afforded the pure α-coupled product **26** (450 mg, 379 μmol, 64%): *R*_f 0.57 (EtOAc/toluene, 1/4, v/v); [α]_D²² +62 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2106, 1805, 1759, 1720, 1520, 1242, 1034; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.50–7.43 (m, 2H, H_{arom}), 7.41–7.14 (m, 26H, H_{arom}), 7.07–7.00 (m, 2H, H_{arom}), 5.54 (s, 1H, H-1''), 5.42 (s, 1H, H-1), 5.39 (dd, *J* = 10.7, 2.7 Hz, 1H, H-3''), 5.18 (s, 2H, CH₂), 5.09–4.96 (m, 3H, CH₂, H-1', NH), 4.86 (d, *J* = 4.7 Hz, 1H, H-2), 4.69–4.63 (m, 4H, CH₂ Bn, H-5''), 4.58–4.55 (m, 2H, H-4, CH₂), 4.40–4.37 (m, 2H, H-4'', CH₂ Bn), 4.35–4.25 (m, 4H, H-4', H-3, CH₂ Bn), 4.18 (dd, *J* = 10.6, 3.9 Hz, 1H, H-3'), 4.14–4.05 (m, 3H, H-2'', H-5', H-5), 3.56 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 3.46 (d, *J* = 14.9 Hz, 1H, CH₂ ClAc), 3.39 (dd, *J* = 11.0, 3.9 Hz, 1H, H-2'), 1.13 (d, *J* = 6.2 Hz, 3H, H-6'); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 171.7, 167.5, 166.4 (C=O), 156.7 (C=O Cbz), 138.0, 137.7, 136.3, 135.9, 134.9, 133.3 (C_q Ph), 132.8, 129.0, 128.8, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6 (CH_{arom}), 97.7 (C-1'), 93.1 (C-1''), 85.7 (C-1), 79.1 (C-2), 78.4 (C-3), 76.8 (C-4''), 76.3 (C-4), 75.1, 73.2 (CH₂ Bn), 72.8 (C-3', CH₂ Bn), 72.3 (C-2''), 70.4 (C-5''), 70.2 (C-5'), 69.9 (C-3'), 67.4, 67.0 (CH₂), 66.5 (C-5), 58.8 (C-2'), 50.7 (C-4'), 40.3 (CH₂ ClAc), 16.3 (C-6');

Benzyl 2,4-Di-O-benzyl-3-O-chloroacetyl-α-D-galactopyranosyluronate-(1→3)-4-(N-benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy-D-galactopyranosyl-(1→4)-2-O-benzyl-α-D-galactopyranosiduronyl-3,6-lactone-(1→3)-sn-glycerol (27). Thioglycoside **26** (328 mg) was coupled to glycerol acceptor **9** (4.0 equiv instead of 1.5 equiv) according to the general procedure for glycosylations using Ph₂SO/Tf₂O. The reaction was quenched with triethylamine (5 equiv), and the title compound **27** was purified using size-exclusion chromatography: yield 81% (302 mg, 224 μmol); *R*_f 0.59 (EtOAc/PE, 2/3, v/v); [α]_D²² +99 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2874, 2108, 1803, 1761, 1719, 1028, 696; ¹H NMR

(400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.39–7.16 (m, 33H, H_{arom}), 7.06–6.99 (m, 2H, H_{arom}), 5.53 (d, J = 2.5 Hz, 1H, H-1''), 5.38 (dd, J = 10.6, 2.7 Hz, 1H, H-3''), 5.25–5.12 (m, 2H, CH₂ Bn), 5.05 (d, J = 12.2 Hz, 1H, CH₂ Bn), 4.99–4.97 (m, 2H, NH, H-1'), 4.90–4.86 (m, 2H, H-1, CH₂ Bn), 4.74–4.61 (m, 7H, H-4, H-3, H-5'', CH₂ Bn), 4.58–4.45 (m, 3H, CH₂ Bn), 4.40–4.37 (m, 2H, CH₂ Bn, H-4''), 4.34–4.26 (m, 3H, H-4', CH₂ Bn), 4.21–4.14 (m, 2H, H-5, H-3'), 4.13–4.08 (m, 2H, CH₂ Gro, H-2''), 4.02 (q, J = 6.3 Hz, 1H, H-5'), 3.89 (dd, J = 5.0, 2.2 Hz, 1H, H-2), 3.87–3.82 (m, 1H, CH Gro), 3.70 (dd, J = 10.7, 6.9 Hz, 1H, CH₂ Gro), 3.59–3.52 (m, 3H, CH₂ Gro, CH₂ ClAc), 3.45 (d, J = 14.9 Hz, 1H, CH₂ ClAc), 3.38 (dd, J = 10.9, 3.9 Hz, 1H, H-2'), 1.11 (d, J = 6.3 Hz, 3H, H-6'); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 170.7, 167.5, 166.3 (C=O), 156.7 (C=O Cbz), 138.3, 137.9, 137.6, 137.4, 135.9, 134.9 (C_q Ph), 128.9, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6 (CH_{arom}), 99.3 (C-1), 97.5 (C-1'), 93.0 (C-1''), 80.6 (C-3), 77.2 (CH Gro), 76.8 (C-4''), 75.5 (C-4), 75.1 (CH₂ Bn), 74.5 (CH₂ Bn), 74.3 (C-2), 73.4 (CH₂ Bn), 72.8 (CH₂ Bn, C-3), 72.3 (CH₂ Bn, C-2''), 71.4 (C-5), 71.1 (CH₂ Gro), 70.4 (C-5''), 69.8 (C-3'), 69.5 (CH₂ Gro), 67.4, 67.0 (CH₂), 66.2 (C-5'), 58.7 (C-2'), 50.6 (C-4'), 40.3 (CH₂ ClAc), 16.2 (C-6'); HRMS [M + Na]⁺ calcd for C₇₃H₇₅ClN₄O₁₉Na 1369.46062, found 1369.46265.

Benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-4-(N-benzoyloxycarbonylamino)-2-azido-2,4,6-trideoxy-D-galactopyranosyl-(1 \rightarrow 4)-2-O-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-1,2-di-O-benzyl-sn-glycerol (28). A solution of 302 mg of compound 27 (224 μ mol, 1 equiv), 145 μ L of pyridine (1.79 mmol, 8 equiv), and 51 mg of thiourea (672 μ mol, 3 equiv) in 4 mL of EtOH was stirred at 65 °C for 3 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with aq 1 M HCl, satd aq NaHCO₃, and brine. The organic phase was dried (MgSO₄), filtered, and concentrated under reduced pressure. Flash column chromatography using EtOAc/toluene (1/4 \rightarrow 1/3) gave 218 mg (171 μ mol, 76%) of the title compound 28: R_f 0.62 (EtOAc/PE, 2/3, v/v); [α]_D²² +95 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2924, 2106, 1805, 1759, 1713, 1535, 1034; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.39–7.12 (m, 33H, H_{arom}), 7.11–7.05 (m, 2H, H_{arom}), 5.55 (d, J = 2.2 Hz, 1H, H-1''), 5.15 (m, 2H, CH₂ Bn), 5.09–5.05 (m, 2H, NH, CH₂ Bn), 4.92 (d, J = 4.2 Hz, 1H, H-1'), 4.89–4.83 (m, 2H, H-1, CH₂ Bn), 4.74–4.58 (m, 7H, H-4, H-3, CH₂ Bn, CH₂), 4.55 (s, 1H, H-5'), 4.54–4.44 (m, 3H, CH₂ Bn), 4.43–4.28 (m, 3H, CH₂ Bn, H-4'), 4.24 (s, 1H, H-4''), 4.20–4.11 (m, 3H, H-5, H-3', H-3'), 4.09 (dd, J = 10.7, 3.5 Hz, 1H, CH₂ Gro), 4.00 (q, J = 6.2 Hz, 1H, H-5'), 3.92–3.81 (m, 3H, H-2'', H-2, CH Gro), 3.68 (dd, J = 10.7, 6.9 Hz, 1H, CH₂ Gro), 3.54 (d, J = 5.3 Hz, 2H, CH₂ Gro), 3.36 (dd, J = 11.0, 3.9 Hz, 1H, H-2'), 2.04 (s, 1H, OH), 1.10 (d, J = 6.2 Hz, 3H, H-6'); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 170.6, 168.0 (C=O), 156.7 (C=O Cbz), 138.2, 138.0, 137.8, 137.7, 137.2, 135.8, 134.9 (C_q Ph), 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4 (CH_{arom}), 99.2 (C-1), 97.3 (C-1'), 92.3 (C-1''), 80.5 (C-3), 77.6 (C-4''), 77.1 (CH Gro), 75.1 (C-4), 74.8 (CH₂ Bn), 74.6 (C-2''), 74.3 (CH₂ Bn), 74.2 (C-2), 73.3 (CH₂ Bn), 72.2 (CH₂ Bn), 72.0 (CH₂ Bn), 71.2 (C-5), 71.0 (CH₂ Gro), 70.6 (C-5''), 69.3 (CH₂ Gro, C-3'), 69.0 (C-3''), 67.0, 66.9 (CH₂), 66.2 (C-5'), 58.6 (C-2'), 50.5 (C-4'), 16.1 (C-6'); HRMS [M + Na]⁺ calcd for C₇₁H₇₄N₄O₁₈Na 1293.48903, found 1293.49043.

Benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-2-acetamido-4-(N-benzoyloxycarbonylamino)-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)-2-O-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-1,2-di-O-benzyl-sn-glycerol (29). To an ice-cooled solution of 94 mg of azide 28 (74 μ mol) in 1 mL of pyridine was added 1 mL of freshly distilled thiolacetic acid. The mixture was stirred at room temperature for 4 h, concentrated under reduced pressure, and coevaporated with toluene. Flash column chromatography using EtOAc/PE (1/1 \rightarrow 3/2) afforded

the title acetamide (89 mg, 69 μ mol, 94%): R_f 0.41 (EtOAc/PE, 3/2, v/v); [α]_D²² +97 (c 0.7, CH₂Cl₂); IR (neat, cm⁻¹) 3368, 2924, 1801, 1718, 1668, 1028, 697; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.40–7.19 (m, 33H, H_{arom}), 7.13 (d, J = 6.7 Hz, 2H, H_{arom}), 5.43 (d, J = 8.9 Hz, 1H, NH), 5.24 (d, J = 9.9 Hz, 1H, NH), 5.19–5.12 (m, 2H, CH₂, H-1''), 5.02 (d, J = 12.4 Hz, 1H, CH₂ Bn), 4.94 (d, J = 12.0 Hz, 1H, CH₂ Bn), 4.91–4.77 (m, 4H, CH₂ Bn, H-1', H-1), 4.73–4.59 (m, 6H, CH₂ Bn, H-4, H-3), 4.53–4.37 (m, 6H, CH₂ Bn, H-5''), 4.20–4.05 (m, 5H, H-4', H-4'', H-2', H-5, CH₂ Gro), 3.98 (dd, J = 9.9, 2.7 Hz, 1H, H-3''), 3.93–3.80 (m, 4H, H-2, H-5', CH Gro, H-2''), 3.75–3.65 (m, 2H, H-3', CH₂ Gro), 3.55 (dd, J = 5.0, 1.7 Hz, 2H, CH₂ Gro), 1.71 (s, 3H, CH₃ NHAc), 1.12 (d, J = 6.4 Hz, 3H, H-6'); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 171.2, 170.4, 168.3 (C=O), 156.9 (C=O Cbz), 138.3, 138.1, 137.9, 137.3, 136.4, 134.8 (C_q Ph), 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5 (CH_{arom}), 99.2 (C-1), 96.4 (C-1'), 96.0 (C-1''), 80.9 (C-3), 77.2 (C-4', CH Gro), 75.4 (C-2''), 74.7, 74.5 (CH₂ Bn), 74.2 (C-2), 73.9 (C-4), 73.4 (CH₂ Bn), 73.3 (C-3'), 72.7, 72.3 (CH₂ Bn), 71.2 (C-5 or C-5''), 71.1 (CH₂ Gro, C-5 or C-5''), 69.4 (CH₂ Gro), 69.2 (C-3''), 67.2, 66.6 (CH₂ Bn), 66.4 (C-5'), 52.1 (C-4'), 48.3 (C-2'), 22.8 (CH₃ NHAc), 16.4 (C-6'); HRMS [M + Na]⁺ calcd for C₇₃H₇₈N₂O₁₉Na 1309.50910, found 1309.50940.

α -D-Galactopyranosyluronate-(1 \rightarrow 3)-2-acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)- α -D-galactopyranosyluronate-(1 \rightarrow 3)-sn-glycerol (1). To a solution of 21 mg (16 μ mol, 1 equiv) of compound 29 in 1.5 mL of DCM was added 8.0 mg of TMSONa (71 μ mol, 4.5 equiv). The mixture was stirred for 2.5 h, followed by the addition of 20 μ L of AcOH (355 μ mol, 22.5 equiv), evaporation, and elution over a plug of silica (eluent: EtOAc, then EtOAc/MeOH/H₂O/AcOH 88/10/1/1). After removal of the eluent, the crude product was dissolved in 7 mL of *t*-BuOH/H₂O (5/2 v/v) and stirred under argon atmosphere. A catalytic amount of palladium on activated charcoal and 125 μ L of 1 M aq HCl were added, and the mixture was allowed to stir for 2 days under hydrogen atmosphere. Filtration over Celite, gel filtration (HW-40, 0.15 M Et₃NHOAc in H₂O), and subsequent lyophilization afforded 5.2 mg of the pure title compound 1 (8.3 μ mol, 52% over two steps): ¹H NMR (600 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 290 K) δ 5.07 (d, J = 2.4 Hz, 1H, H-1''), 5.04 (d, J = 3.7 Hz, 1H, H-1), 4.98 (d, J = 4.0 Hz, 1H, H-1'), 4.79 (q, J = 6.7 Hz, 1H, H-5'), 4.37 (d, J = 2.7 Hz, 1H, H-4), 4.34 (s, 1H, H-5), 4.27–4.25 (m, 2H, H-4'', H-3'), 4.14 (s, 1H, H-5''), 4.11 (dd, J = 11.4, 4.0 Hz, 1H, H-2'), 4.07 (dd, J = 10.6, 3.1 Hz, 1H, H-3), 3.96–3.91 (m, 1H, CH Gro), 3.89 (dd, J = 10.6, 3.8 Hz, 1H, H-2), 3.85 (m, 2H, H-2'', H-3''), 3.84–3.78 (m, 2H, H-4', CH₂ Gro), 3.66 (dd, J = 11.8, 4.6 Hz, 1H, CH₂ Gro), 3.58 (dd, J = 11.8, 6.2 Hz, 1H, CH₂ Gro), 3.53 (dd, J = 10.6, 7.0 Hz, 1H, CH₂ Gro), 2.02 (s, 3H, CH₃ NHAc), 1.26 (d, J = 6.7 Hz, 3H, H-6'); ¹³C NMR (151 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 290 K) δ 175.6, 175.5, 174.7 (C=O), 99.6 (C-1), 99.1 (C-1'), 98.9 (C-1''), 80.0 (C-4), 73.3 (C-3'), 73.2 (C-5''), 71.5 (CH Gro), 71.3 (C-4'', C-5), 70.1 (C-3', CH₂ Gro), 69.4 (C-3), 68.8 (C-2), 68.0 (C-2'), 63.7 (C-5'), 63.2 (CH₂ Gro), 53.5 (C-4'), 48.4 (C-2'), 23.0 (CH₃ NHAc), 16.3 (C-6'); ¹³C-HMBC NMR (151 MHz, D₂O, T = 290 K) δ 99.6 (J_{C1-H1} = 171.1 Hz, C-1), 99.1 ($J_{C1'-H1'}$ = 174.4 Hz, C-1'), 98.9 ($J_{C1''-H1''}$ = 171.1 Hz, C-1''); HRMS [M + H]⁺ calcd for C₂₃H₃₉N₂O₁₈ 631.21924, found 631.21934.

2,4-Di-O-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-1,2-di-O-benzyl-sn-glycerol (30). 448 mg of lactone 4 was coupled to alcohol 9 according to the general procedure for glycosidations using Ph₂SO/Tf₂O, yielding 567 mg of the title compound 30 (928 μ mol, α/β 10:1, 93%): flash column chromatography gradient EtOAc/PE (1/9 \rightarrow 1/4); R_f 0.73 (EtOAc/toluene, 1/5, v/v); IR (neat, cm⁻¹) 3030, 2868, 1798, 1454, 1057, 696; NMR assignment of the major anomer (α), ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.37–7.25 (m, 18H, H_{arom}), 7.19 (dd, J = 6.7, 2.7 Hz, 2H,

H_{arom}), 4.86–4.83 (m, 2H, H-1, CH₂ Bn), 4.71–4.61 (m, 3H, H-3, CH₂ Bn), 4.56 (s, 2H, CH₂ Bn), 4.51 (d, $J = 4.6$ Hz, 2H, CH₂ Bn), 4.48–4.43 (m, 2H, H-4, CH₂ Bn), 4.14 (t, $J = 1.6$ Hz, 1H, H-5), 4.08 (dd, $J = 10.7$, 3.6 Hz, 1H, CH₂ Gro), 3.88 (dd, $J = 5.0$, 2.4 Hz, 1H, H-2), 3.86–3.81 (m, 1H, CH Gro), 3.67 (dd, $J = 10.7$, 6.9 Hz, 1H, CH₂ Gro), 3.54 (dd, $J = 5.7$, 4.7 Hz, 2H, CH₂ Gro); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 171.5 (C=O), 138.3, 137.8, 137.4, 136.6 (C_q Ph), 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.7, 127.6, 127.5 (CH_{arom}), 99.2 (C-1), 80.1 (C-3), 77.1 (CH Gro), 75.4 (C-5), 74.3 (C-2), 74.2 (CH₂ Bn), 73.2 (CH₂ Bn), 72.1 (CH₂ Bn), 71.8 (C-4), 71.3 (CH₂ Bn), 71.0 (CH₂ Gro), 69.4 (CH₂ Gro); HRMS [M + Na]⁺ calcd for C₃₇H₃₈O₈Na 633.24589, found 633.24698.

Benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (31). To a solution of 831 mg of lactone **30** (1.36 mmol, 1 equiv) in 14 mL of DCM was added 160 mg of TMSO₂Na (1.43 mmol, 1.05 equiv). After 30 min, TLC indicated complete consumption of the starting material, and the mixture was evaporated and filtered through a plug of silica gel using EtOAc/toluene/AcOH (20/79/1) as eluent. After removal of the eluent, the crude acid was dissolved in 14 mL of DMF. Next, 154 μ L of BnBr (1.28 mmol, 1.1 equiv) and 418 mg of Cs₂CO₃ (1.28 mmol, 1.1 equiv) were added, and the reaction was stirred for 2 h. The mixture was diluted with EtOAc and washed with H₂O and brine. Drying over MgSO₄, filtration, and concentration under reduced pressure gave the crude product, which was purified by flash column chromatography using EtOAc/PE (1/4 \rightarrow 1/3) to give ester **31** (729 mg, 1.01 mmol, 75% over two steps): R_f 0.52 (EtOAc/toluene, 1/3, v/v); [α]_D²² +44 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 3030, 2870, 1759, 1454, 1107, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.36–7.15 (m, 25H, H_{arom}), 5.09–4.95 (m, 3H, CH₂ Bn, H-1), 4.71 (d, $J = 11.7$ Hz, 1H, CH₂ Bn), 4.65–4.55 (m, 4H, CH₂ Bn), 4.49 (s, 3H, CH₂ Bn, H-5), 4.45 (d, $J = 11.7$ Hz, 1H, CH₂ Bn), 4.22 (dd, $J = 3.1$, 1.5 Hz, 1H, H-4), 4.11–4.05 (m, 1H, H-3), 3.88–3.80 (m, 2H, H-2, CH₂ Gro), 3.77–3.70 (m, 1H, CH Gro), 3.58 (d, $J = 5.0$ Hz, 2H, CH₂ Gro), 3.53 (dd, $J = 10.4$, 5.5 Hz, 1H, CH₂ Gro), 2.28 (d, $J = 4.6$ Hz, 1H, OH); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 168.5 (C=O), 138.4, 138.3, 138.1, 138.0, 135.0 (C_q Ph), 128.6, 128.5, 128.4, 128.3, 128.3, 128.2, 127.9, 127.6, 127.5 (CH_{arom}), 97.4 (C-1), 78.0 (C-4), 76.7 (CH Gro), 76.6 (C-2), 74.9 (CH₂ Bn), 73.4 (CH₂ Bn), 72.6 (CH₂ Bn), 71.9 (CH₂ Bn), 70.4 (C-5), 69.7 (CH₂ Bn, C-3), 68.4 (CH₂ Gro), 66.9 (CH₂ COOBn); HRMS [M + Na]⁺ calcd for C₄₄H₄₆O₉Na 741.30340, found 741.30352.

1,2,4-Tri-O-benzyl-1-(1,2-di-O-benzyl-*sn*-glycerol)-D-galactopyranosiduronic Acid 3,6-Lactone (32). To a mixture of 57 mg of lactone **30** (93 μ mol, 1 equiv), 96 μ L of benzyl alcohol (933 μ mol, 10 equiv), and 9.5 μ L of thiophenol (93 μ mol, 1 equiv) in 2 mL of dichloromethane was added 11 μ L of SnCl₄ (93 μ mol, 1 equiv). After being stirred for 2 days at ambient temperature, the mixture was neutralized with triethylamine, and 1 mL of satd aq NaHCO₃ was added. After rigorous stirring for 1 hr, the mixture was filtrated through a plug of Celite, and the solid material was rinsed with dichloromethane. The filtrate was washed with satd aq NaHCO₃ and brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. Purification by size-exclusion chromatography (DCM/MeOH 1/1 v/v) and flash column chromatography (eluent: EtOAc/PE 1/3) gave the title compound **32** (34 mg, 47 μ mol, 51%) as an epimeric mixture: R_f 0.42 (EtOAc/toluene, 1/4, v/v); IR (neat, cm⁻¹) 3420, 2875, 1791, 1454, 1100, 1061, 698; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, galacturonic acid based numbering, major epimer) δ 7.36–7.10 (m, 25H, H_{arom}), 4.81 (d, $J = 7.2$ Hz, 1H, H-1), 4.80–4.73 (m, 2H, CH₂ Bn), 4.65 (d, $J = 2.2$ Hz, 2H, CH₂ Bn), 4.62–4.57 (m, 2H, CH₂ Bn), 4.53 (dd, $J = 6.8$, 1.7 Hz, 1H, H-3), 4.49 (s, 2H, CH₂ Bn), 4.43 (dd, $J = 6.8$, 4.5 Hz, 1H, H-5), 4.33 (d, $J = 11.7$ Hz, 1H, CH₂ Bn), 4.28 (d, $J = 11.5$ Hz, 1H, CH₂ Bn), 4.11 (t, $J = 6.8$ Hz, 1H, H-4), 3.88–3.81 (m, 1H, CH₂ Gro), 3.81–3.74 (m, 2H, CH₂ Gro, CH Gro), 3.63–3.56 (m, 3H, H-2, CH₂

Gro), 2.85 (s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC, galacturonic acid based numbering, major epimer) δ 174.4 (C=O), 138.0, 137.3, 137.2, 137.0 (C_q Ph), 128.5, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5 (CH_{arom}), 103.4 (C-1), 79.5 (C-3, C-4), 77.1 (CH Gro), 76.3 (C-2), 74.4 (CH₂ Bn), 74.3 (C-5), 73.4 (CH₂ Bn), 72.2 (CH₂ Bn), 71.9 (CH₂ Bn), 70.5 (CH₂ Bn), 69.7 (CH₂ Gro), 69.3 (CH₂ Gro); HRMS [M + Na]⁺ calcd for C₄₄H₄₆O₉Na 741.30340, found 741.30347.

4-(N-Benzyloxycarbonylamino)-2-azido-3-O-chloroacetyl-2,4,6-trideoxy-D-galactopyranosyl-(1 \rightarrow 4)-phenyl 2-O-Benzyl-1-thio- β -D-galactopyranosidurono-3,6-lactone (33). A mixture of 441 mg of hemiacetal **7** (1.11 mmol, 1 equiv), 559 mg of diphenyl sulfoxide (2.76 mmol, 2.5 equiv), and 330 mg of tri-*tert*-butylpyrimidine (1.33 mmol, 1.2 equiv) was coevaporated with toluene and stirred over activated molecular sieves (3 Å) for 30 min in 10 mL of DCM. The mixture was cooled to –60 °C before 202 μ L of triflic acid anhydride (1.22 mmol, 1.1 equiv) was added. The mixture was allowed to warm to –40 °C before a mixture (dried over 3 Å molecular sieves) of 792 mg of acceptor **5** (2.21 mmol, 2 equiv) and 330 mg of tri-*tert*-butylpyrimidine (1.33 mmol, 1.2 equiv) in 2 mL of DCM was added. Stirring was continued, and the reaction mixture was allowed to warm to 4 °C overnight. The reaction mixture was quenched with 769 μ L of triethylamine (5.53 mmol, 5.0 equiv), diluted with DCM, and washed with satd aq NaHCO₃. The aqueous phase was extracted with DCM, and the combined organic phases were dried (MgSO₄), filtered, and concentrated under reduced pressure. Purification by size-exclusion chromatography (DCM/MeOH 1/1 v/v) and flash column chromatography (eluent: EtOAc/PE 1/4 \rightarrow 3/7) gave the title compound **33** as a white foam (690 mg, 933 μ mol, 84%): R_f 0.68 (EtOAc/PE, 2/3, v/v); [α]_D²² –38 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2112, 1805, 1717, 1514, 1042; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.48–7.27 (m, 15H, H_{arom}), 5.42 (s, 1H, H-1), 5.24–5.12 (m, 2H, H-3', CH₂ Cbz), 5.08–4.96 (m, 3H, CH₂ Cbz, NH, H-1'), 4.89 (dd, $J = 4.9$, 1.5 Hz, 1H, H-3), 4.69 (d, $J = 11.8$ Hz, 1H, CH₂ Bn), 4.63–4.54 (m, 2H, CH₂ Bn, H-4), 4.30 (d, $J = 4.8$ Hz, 1H, H-2), 4.27–4.20 (m, 2H, H-5', H-4'), 4.11 (s, 1H, H-5), 3.98–3.83 (m, 2H, CH₂ ClAc), 3.48 (dd, $J = 11.1$, 3.8 Hz, 1H, H-2'), 1.17 (d, $J = 6.4$ Hz, 3H, H-6'); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 171.7, 166.5 (C=O), 156.6 (C=O Cbz), 136.3, 136.1, 133.2 (C_q Ph), 132.8, 129.0, 128.8, 128.6, 128.4, 128.3, 128.1, 128.0 (CH_{arom}), 97.9 (C-1'), 85.7 (C-1), 79.1 (C-3), 78.4 (C-2), 76.6 (C-4), 73.2 (CH₂ Bn), 71.6 (C-3'), 70.2 (C-5), 67.3 (CH₂ Cbz), 65.7 (C-5'), 57.1 (C-2'), 52.2 (C-4'), 40.5 (CH₂ ClAc), 16.3 (C-6'); HRMS [M + Na]⁺ calcd for C₃₅H₃₅ClN₄O₁₀SNa 761.16546, found 761.16560.

4-(N-Benzyloxycarbonylamino)-2-azido-3-O-chloroacetyl-2,4,6-trideoxy-D-galactopyranosyl-(1 \rightarrow 4)-2-O-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (34). Lactone **33** (538 mg) was coupled to alcohol **31** (2 equiv instead of 1.5 equiv) according to the general procedure for glycosylations using Ph₂SO/Tf₂O. The reaction was quenched with triethylamine (5 equiv), and the title compound **34** was obtained in 60% yield (590 mg, 438 μ mol) after size-exclusion chromatography (DCM/MeOH 1/1 v/v): R_f 0.58 (EtOAc/toluene, 1/3, v/v); [α]_D²² +101 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2110, 1803, 1761, 1720, 1454, 1043; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.43–7.01 (m, 35H, H_{arom}), 5.17–5.14 (m, 2H, H-3'', CH₂ Bn), 5.08–4.94 (m, 6H, CH₂ Bn, H-1', H-1, NH), 4.89–4.80 (m, 3H, H-1'', CH₂ Bn), 4.73–4.69 (m, 2H, H-4', H-3'), 4.66–4.59 (m, 2H, CH₂ Bn), 4.57–4.48 (m, 4H, CH₂ Bn), 4.46 (s, 1H, H-5), 4.41–4.33 (m, 3H, H-3, CH₂ Bn), 4.25–4.21 (m, 3H, H-4, H-5', H-4''), 4.18 (q, $J = 6.6$ Hz, 1H, H-5''), 3.99 (dd, $J = 10.1$, 3.5 Hz, 1H, H-2), 3.89 (d, $J = 4.6$ Hz, 2H, CH₂ ClAc), 3.88–3.80 (m, 2H, CH₂ Gro, H-2'), 3.80–3.74 (m, 1H, CH Gro), 3.65–3.57 (m, 3H, CH₂ Gro), 3.42 (dd, $J = 11.2$, 3.8 Hz,

1H, H-2''), 1.14 (d, $J = 6.4$ Hz, 3H, H-6''); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 170.7, 168.2, 166.5 (C=O), 156.5 (CH_2 Cbz), 138.6, 138.5, 138.2, 137.9, 137.1, 136.0, 134.8 (C_q Ph), 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.5, 127.4, 127.2, 126.9 (CH_{arom}), 98.4 (C-1), 97.7 (C-1''), 94.9 (C-1'), 80.5 (C-3'), 76.5 (CH Gro), 75.7 (C-4), 75.5 (C-4'), 75.4 (C-3), 74.9 (C-2'), 74.7 (CH_2 Bn), 74.2 (CH_2 Bn), 73.9 (C-2), 73.3 (2 CH_2 Bn), 71.9 (CH_2 Bn), 71.5 (C-3''), 71.2 (C-5'), 70.1 (C-5), 69.7 (CH_2 Gro), 68.6 (CH_2 Gro), 67.3 (CH_2), 67.1 (CH_2), 65.4 (C-5''), 56.9 (C-2''), 52.1 (C-4''), 40.5 (CH_2 ClAc), 16.2 (C-6''); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{73}\text{H}_{75}\text{ClN}_4\text{O}_{19}\text{Na}$ 1369.46062, found 1369.46158.

4-(*N*-Benzyloxycarbonylamino)-2-azido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)-2-*O*-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 4)-benzyl 2,4-di-*O*-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-1,2-di-*O*-benzyl-*sn*-glycerol (35). A solution of 76 mg of compound 34 (56 μmol , 1 equiv), 36 μL of pyridine (451 μmol , 8 equiv), and 13 mg (169 μmol , 3 equiv) of thiourea in 1 mL of EtOH was stirred at 65 $^\circ\text{C}$ for 6 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with aq 1 M HCl, satd aq NaHCO_3 , and brine. The organic phase was dried (MgSO_4), filtered, and concentrated in vacuo. Flash column chromatography using EtOAc/PE (7/13 \rightarrow 9/11) gave 44 mg (34 μmol , 62%) of the title compound 35: R_f 0.48 (EtOAc/PE, 3/7, v/v); $[\alpha]_D^{22} +97$ (c 1.0, CH_2Cl_2); IR (neat, cm^{-1}) 3400, 2874, 2110, 1081, 1717, 1705, 1028; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.45–6.99 (m, 35H, H_{arom}), 5.12 (s, 2H, CH_2 Bn), 5.08–4.98 (m, 4H, NH, CH_2 Bn, H-1'), 4.96 (d, $J = 3.6$ Hz, 1H, H-1), 4.87–4.78 (m, 3H, CH_2 , H-1''), 4.71 (dd, $J = 4.9$, 1.8 Hz, 1H, H-3'), 4.69 (s, 1H, H-4'), 4.67–4.59 (m, 2H, CH_2 Bn), 4.58–4.48 (m, 4H, CH_2 Bn), 4.46 (s, 1H, H-5), 4.42–4.32 (m, 3H, CH_2 Bn, H-3), 4.23 (s, 2H, H-4, H-5'), 4.09 (m, 2H, H-3'', H-5''), 4.03–3.96 (m, 2H, H-4'', H-2), 3.85 (dd, $J = 10.4$, 4.5 Hz, 1H, CH_2 Gro), 3.81 (dd, $J = 4.6$, 2.5 Hz, 1H, H-2'), 3.79–3.73 (m, 1H, CH Gro), 3.65–3.55 (m, 3H, CH Gro), 3.14 (dd, $J = 10.7$, 3.8 Hz, 1H, H-2''), 1.13 (d, $J = 6.4$ Hz, 3H, H-6''); ^{13}C NMR (100 MHz, CDCl_3 , HH-COSY, HSQC) δ 171.1, 168.3 (C=O), 158.0 (CH_2 Cbz), 138.6, 138.5, 138.2, 137.9, 137.2, 135.7, 134.9 (C_q Ph), 128.7, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.40, 127.2, 126.9 (CH_{arom}), 98.5 (C-1), 98.4 (C-1''), 94.9 (C-1'), 80.6 (C-3'), 76.6 (CH Gro), 75.9 (C-4'), 75.8 (C-4), 75.5 (C-3), 74.9 (C-2'), 74.7, 74.2 (CH_2 Bn), 73.9 (C-2), 73.4, 73.3, 71.9 (CH_2 Bn), 71.4 (C-5'), 70.1 (C-5), 69.7, 68.6 (CH_2 Gro), 68.4 (C-3''), 67.6, 67.1 (CH_2), 65.8 (C-5''), 59.9 (C-2''), 55.5 (C-4''), 16.4 (C-6''); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{71}\text{H}_{74}\text{N}_4\text{O}_{18}\text{Na}$ 1293.48903, found 1293.48964.

4-(*N*-Benzyloxycarbonylamino)-2-acetamido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)-2-*O*-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 4)-benzyl 2,4-di-*O*-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-1,2-di-*O*-benzyl-*sn*-glycerol (36). To an ice-cooled solution of 281 mg of azide 35 (221 μmol) in 5 mL of pyridine was added 5 mL of freshly distilled thiolacetic acid. The mixture was stirred at room temperature for 2.5 h, concentrated under reduced pressure, and coevaporated with toluene. Flash column chromatography using EtOAc/PE (7/3 \rightarrow 1/0) afforded the title acetamide (188 mg, 146 μmol , 66%): R_f 0.30 (EtOAc/PE, 3/1, v/v); $[\alpha]_D^{22} +83$ (c 0.8, CH_2Cl_2); IR (neat, cm^{-1}) 3300, 2924, 1801, 1759, 1717, 1661, 1540, 1028; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC) δ 7.51–6.91 (m, 35H, H_{arom}), 5.67 (d, $J = 8.4$ Hz, 1H, NH), 5.40 (d, $J = 9.7$ Hz, 1H, NH), 5.18–4.99 (m, 5H, CH_2 Bn, H-1'), 4.95 (d, $J = 3.5$ Hz, 1H, H-1), 4.91 (d, $J = 3.7$ Hz, 1H, H-1''), 4.84–4.80 (m, 2H, CH_2 Bn), 4.69 (dd, $J = 4.9$, 1.5 Hz, 1H, H-3'), 4.66 (s, 1H, H-4'), 4.62 (m, 2H, CH_2 Bn), 4.59–4.48 (m, 4H, CH_2 Bn), 4.45 (s, 1H, H-5), 4.42–4.31 (m, 3H, CH_2 Bn, H-3), 4.22 (s, 1H, H-4), 4.12 (s, 1H, H-5'), 4.06–3.96 (m, 4H, H-2'', H-4'', H-5'', H-2), 3.86–3.73 (m, 4H, CH_2 Gro, H-3'', H-2', CH Gro), 3.65–3.56 (m, 3H, CH_2 Gro), 1.92 (s, 3H, CH_3 NHAc), 1.12 (d, $J = 6.2$ Hz, 3H, H-6''); ^{13}C NMR

(100 MHz, CDCl_3 , HH-COSY, HSQC) δ 171.5, 168.2 (C=O), 157.7 (CH_2 Cbz), 138.4, 138.3, 138.2, 137.8, 137.1, 136.0, 134.8 (C_q Ph), 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.6, 127.4, 127.3, 127.0, 126.7 (CH_{arom}), 98.4 (C-1), 97.5 (C-1''), 94.9 (C-1'), 80.9 (C-3'), 76.4 (CH Gro), 75.7 (C-4), 75.6 (C-3), 74.7, 74.6 (C-2', C-4', CH_2 Bn), 74.0 (CH_2 Bn), 73.7 (C-2), 73.4, 73.1, 71.7 (CH_2 Bn), 71.3 (C-5'), 70.0 (C-5), 69.6, 68.4 (CH_2 Gro), 67.7 (C-3''), 67.0, 66.9 (CH_2), 66.1 (C-5''), 55.2 (C-4''), 50.2 (C-2''), 22.9 (CH_3 NHAc), 16.4 (C-6''); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{73}\text{H}_{78}\text{N}_2\text{O}_{19}\text{Na}$ 1309.50910, found 1309.50986.

2-Acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)- α -D-galactopyranosyluronate-(1 \rightarrow 3)- α -D-galactopyranosyluronate-(1 \rightarrow 3)-*sn*-glycerol (2). Compound 36 (54 mg, 42 μmol , 1 equiv) was dissolved in 7 mL of *t*-BuOH/ H_2O (5/2 v/v) and stirred under argon atmosphere. A catalytic amount of palladium on activated charcoal and 105 μL of 1 M aq HCl were added, and the mixture was allowed to stir for 2 days under hydrogen atmosphere. Following filtration over Celite and removal of the eluent, the crude product was allowed to stir in 0.04 M aq HCl for an additional 2 days. Next, the mixture was concentrated in vacuo and purified by ion-exchange column chromatography (30 mM NaOAc (aq)/100 mM NaOH (aq) \rightarrow 80 mM NaOAc (aq)/100 mM NaOH (aq)) and filtration (HW-40, 0.15 M Et_3NHOAc in H_2O) to afford 10 mg of the pure title compound 2 (16 μmol , 38%) after lyophilization: ^1H NMR (600 MHz, D_2O , HH-COSY, HSQC, HMBC, TOCSY, $T = 293$ K) δ 5.32 (d, $J = 3.8$ Hz, 1H, H-1'), 5.08 (d, $J = 3.8$ Hz, 1H, H-1), 5.03 (d, $J = 3.8$ Hz, 1H, H-1''), 4.85 (q, $J = 6.5$ Hz, 1H, H-5''), 4.68 (s, 1H, H-5'), 4.60 (d, $J = 1.9$ Hz, 1H, H-4), 4.44 (d, $J = 2.4$ Hz, 1H, H-4'), 4.39 (s, 1H, H-5), 4.27 (dd, $J = 11.3$, 4.3 Hz, 1H, H-3''), 4.21–4.18 (m, 2H, H-3', H-3), 4.09 (dd, $J = 11.3$, 3.8 Hz, 1H, H-2''), 4.04–3.95 (m, 3H, H-2, CH Gro, H-2'), 3.88 (dd, $J = 10.6$, 3.6 Hz, 1H, CH_2 Gro), 3.74 (dd, $J = 11.8$, 4.5 Hz, 1H, CH_2 Gro), 3.70 (d, $J = 3.7$ Hz, 1H, H-4''), 3.66 (dd, $J = 11.8$, 6.2 Hz, 1H, CH_2 Gro), 3.57 (dd, $J = 10.5$, 7.1 Hz, 1H, CH_2 Gro), 2.17 (s, 3H, CH_3 NHAc), 1.33 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (151 MHz, D_2O , HH-COSY, HSQC, HMBC, TOCSY, $T = 293$ K) δ 176.1, 176.0, 175.3 (C=O), 99.7 (C-1'', C-1), 96.9 (C-1'), 81.0 (C-4'), 76.2 (C-3), 72.1, 72.0 (C-5, C-5'), 71.5 (CH Gro), 70.0 (CH_2 Gro), 69.4 (C-3'), 68.8 (C-2'), 68.5 (C-4), 67.5 (C-2), 65.5 (C-3''), 64.2 (C-5), 63.2 (CH_2 Gro), 56.2 (C-4''), 50.2 (C-2''), 23.2 (CH_3 NHAc), 16.3 (C-6''); ^{13}C -HMBC NMR (151 MHz, D_2O , $T = 293$ K) δ 99.7 ($J_{\text{C}1''-\text{H}1''} = 173.31$ Hz, $J_{\text{C}1-\text{H}1} = 170.6$ Hz, C-1'', C-1), 96.9 ($J_{\text{C}1'-\text{H}1'} = 170.3$ Hz, C-1'); HRMS [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{23}\text{H}_{39}\text{N}_2\text{O}_{18}$ 631.21924, found 631.21928.

(1,3-Oxazolidino-2-one)[5,4-*c*]-2-acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 4)- α -D-galactopyranosyluronate-(1 \rightarrow 3)- α -D-galactopyranosyluronate-(1 \rightarrow 3)-*sn*-glycerol (37). To a solution of 40.0 mg (31 μmol , 1 equiv) of compound 36 in 1.5 mL of DCM was added 14 mg of TMSO $_n$ (124 μmol , 4.0 equiv). The mixture was stirred for 1 h, followed by evaporation of the solvent and elution of the crude product over a plug of silica (eluent: EtOAc, then EtOAc/MeOH/ H_2O /AcOH 93/5/1/1, then EtOAc/MeOH/ H_2O /AcOH 88/10/1/1). After removal of the eluent, the crude product was dissolved in 5 mL of *t*-BuOH/ H_2O (4/1 v/v) and stirred under argon atmosphere. A catalytic amount of palladium on activated charcoal and 190 μL of 1 M aq HCl were added, and the mixture was allowed to stir overnight under hydrogen atmosphere. Filtration over Celite, followed by gel filtration (HW-40, 0.15 M Et_3NHOAc in H_2O) and subsequent lyophilization, afforded 8.95 mg of the title compound 37 (11.8 μmol , 38% over two steps): ^1H NMR (600 MHz, D_2O , HH-COSY, HSQC, $T = 306$ K) δ 5.22 (d, $J = 3.8$ Hz, 1H, H-1'), 4.99 (d, $J = 3.8$ Hz, 1H, H-1), 4.95 (d, $J = 3.8$ Hz, 1H, H-1''), 4.79 (dd, $J = 9.0$, 7.2 Hz, 1H, H-3''), 4.70–4.61 (m, 2H, H-5', H-5''), 4.52 (d, $J = 2.0$ Hz, 1H, H-4), 4.40–4.33 (m, 2H, H-5, H-4'), 4.16–4.06 (m, 4H, H-4'', H-3', H-2'', H-3), 3.94–3.86 (m, 3H, H-2,

CH Gro, H-2'), 3.78 (dd, $J = 10.5, 3.7$ Hz, 1H, CH₂ Gro), 3.64 (dd, $J = 11.8, 4.6$ Hz, 1H, CH₂ Gro), 3.56 (dd, $J = 11.8, 6.2$ Hz, 1H, CH₂ Gro), 3.49 (dd, $J = 10.6, 7.0$ Hz, 1H, CH₂ Gro), 3.19 (q, $J = 7.3$ Hz, 10H, CH₂ Et₃NHOAc), 2.07 (s, 3H, CH₃ NHAc), 1.28–1.24 (m, 18H, H-6'', CH₃ Et₃NHOAc); ¹³C NMR (151 MHz, D₂O, HH-COSY, HSQC, $T = 306$ K) δ 175.5, 175.3, 174.8, 162.7 (C=O), 99.8 (C-1), 99.2 (C-1''), 96.9 (C-1'), 80.9 (C-4'), 76.7 (C-3''), 76.1 (C-3), 71.9, 71.8 (C-5, C-5'), 71.6 (CH Gro), 70.1 (CH₂ Gro), 69.5 (C-3'), 68.8 (C-2'), 68.4 (C-4), 67.5 (C-2), 63.3 (CH₂ Gro), 63.1 (C-5''), 56.9 (C-4''), 50.7 (C-2''), 47.6 (CH₂ Et₃NHOAc), 23.2 (CH₃ NHAc), 17.0 (C-6''), 9.2 (CH₃ Et₃NHOAc); ¹³C-HMBC NMR (151 MHz, D₂O, $T = 306$ K) δ 99.9 ($J_{C1-H1} = 170.9$ Hz, C-1), 98.8 ($J_{C1'-H1''} = 172.5$ Hz, C-1''), 97.1 ($J_{C1'-H1'} = 172.0$ Hz, C-1'); HRMS [M + H]⁺ calcd for C₂₄H₃₇N₂O₁₉ 657.19850, found 657.19866.

2,4-Di-O-benzyl- α -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-4-(N-benzoyloxycarbonylamino)-2-azido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (38). Lactone 4 (257 mg) was coupled to 220 mg of alcohol 20 (382 μ mol, 0.66 equiv) according to the general procedure for glycosidations using Ph₂SO/Tf₂O, yielding 244 mg of the title compound 38 (267 μ mol, 70%) after size-exclusion chromatography (DCM/MeOH 1/1 v/v) and flash column chromatography (eluent: EtOAc/PE 1/3 \rightarrow 3/7); R_f 0.68 (EtOAc/toluene, 1/4, v/v); [α]_D²² +106 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2872, 2110, 1798, 1717, 1454, 1026, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.55–7.11 (m, 25H, H_{arom}), 5.14 (d, $J = 2.3$ Hz, 1H, H-1'), 5.13–4.99 (m, 3H, NH, CH₂ Cbz), 4.82 (d, $J = 3.8$ Hz, 1H, H-1), 4.79 (d, $J = 11.7$ Hz, 1H, CH₂ Bn), 4.73–4.61 (m, 3H, CH₂ Bn, H-3'), 4.58–4.47 (m, 5H, CH₂ Bn, H-4'), 4.29–4.17 (m, 3H, CH₂ Bn, H-5', H-3), 4.10 (dd, $J = 5.0, 2.3$ Hz, 1H, H-2'), 4.01 (dd, $J = 9.6, 2.9$ Hz, 1H, H-4), 3.94 (q, $J = 6.1$ Hz, 1H, H-5), 3.82–3.73 (m, 2H, CH Gro, CH₂ Gro), 3.62 (d, $J = 4.5$ Hz, 2H, CH₂ Gro), 3.60–3.53 (m, 1H, CH₂ Gro), 3.15 (dd, $J = 10.8, 3.8$ Hz, 1H, H-2), 1.05 (d, $J = 6.4$ Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 171.9 (C=O), 156.6 (C=O Cbz), 138.3, 138.0, 136.8, 135.8 (C_q Ph), 127.7, 128.5, 128.5, 128.3, 128.0, 127.7, 127.6, 127.4 (CH_{arom}), 98.2 (C-1), 95.6 (C-1'), 80.4 (C-3'), 76.7 (CH Gro), 75.8 (C-4'), 75.1 (C-2'), 74.3 (CH₂ Bn), 73.5 (C-3), 73.4 (CH₂ Bn), 72.0 (CH₂ Bn, C-5'), 71.4 (CH₂ Bn), 69.3 (CH₂ Bn), 67.9 (CH₂ Bn), 67.0 (CH₂ Cbz), 64.2 (C-5), 58.3 (C-2), 51.8 (C-4), 16.4 (C-6); HRMS [M + Na]⁺ calcd for C₅₁H₅₄N₄O₁₂Na 937.36304, found 937.36340.

Benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-4-(N-benzoyloxycarbonylamino)-2-azido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (39). To a solution of 88 mg of lactone 38 (96 μ mmol, 1 equiv) in 2 mL of DCM was added 13 mg of TMSONa (115 μ mol, 1.2 equiv). After 50 min, TLC indicated complete consumption of the starting material, and the reaction was quenched with 28 μ L of AcOH (481 μ mol, 5.0 equiv), after which the mixture was coevaporated with toluene and subsequently dissolved in 2 mL of DMF. Next, 17 μ L of BnBr (144 μ mol, 1.5 equiv) and 39 mg of Cs₂CO₃ (120 μ mol, 1.25 equiv) were added, and the reaction was stirred until TLC analysis showed complete consumption of the starting material. The mixture was diluted with EtOAc and washed with H₂O and brine. Drying over MgSO₄, filtration, and concentration under reduced pressure gave the crude product. Purification by flash column chromatography using EtOAc/toluene (1/4) gave the title compound 39 in pure form (86 mg, 84 μ mol, 88% over two steps); R_f 0.46 (EtOAc/toluene, 1/3, v/v); [α]_D²² +122 (c 1.0, CH₂Cl₂); IR (neat, cm⁻¹) 2880, 2104, 1761, 1719, 1094, 1026, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.37–7.07 (m, 30H, H_{arom}), 5.59 (d, $J = 3.0$ Hz, 1H, H-1'), 5.11–4.96 (m, 4H, NH, CH₂ Bn), 4.88 (d, $J = 3.8$ Hz, 1H, H1), 4.75 (d, $J = 12.2$ Hz, 1H, CH₂ Bn), 4.70–4.58 (m, 5H, H-5', CH₂ Bn), 4.55–4.45 (m, 2H, CH₂ Bn), 4.40 (m, 2H, CH₂ Bn), 4.28–4.20 (m, 4H, H-4', H-4,

H-3, H-3'), 3.97–3.90 (m, 2H, H-2', H-5), 3.81–3.70 (m, 2H, CH₂ Gro, CH Gro), 3.61–3.53 (m, 3H, CH₂ Gro), 3.30 (dd, $J = 10.5, 3.9$ Hz, 1H, H-2), 2.18 (d, $J = 4.0$ Hz, 1H, OH), 1.03 (d, $J = 6.4$ Hz, 3H, H-6); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 168.1 (C=O COOBn), 156.8 (C=O Cbz), 138.3, 138.1, 138.0, 137.8, 135.9, 134.9 (C_q Ph), 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 127.4 (CH_{arom}), 97.7 (C-1), 92.3 (C-1'), 77.6 (C-4'), 76.8 (CH Gro), 74.8 (CH₂ Bn), 74.8 (C-2'), 73.3 (CH₂ Bn), 72.1, 72.0 (CH₂ Bn), 70.6 (C-5'), 69.5 (C-3), 69.3 (CH₂ Gro), 69.1 (C-3'), 67.9 (CH₂ Gro), 66.9, 66.9 (CH₂ Cbz, CH₂ COOBn), 65.0 (C-5), 59.2 (C-2), 50.8 (C-4), 16.2 (C-6); HRMS [M + Na]⁺ calcd for C₅₈H₆₂N₄O₁₃Na 1045.42056, found 1045.42095.

2,4-Di-O-benzyl- α / β -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-4-(N-benzoyloxycarbonylamino)-2-azido-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (40). Lactone 4 (62 mg, 139 μ mol) was coupled to 95 mg of alcohol 39 (93 μ mol, 0.67 equiv) according to the general procedure for glycosidations using Ph₂SO/Tf₂O, yielding 99 mg of the title epimers (73 μ mol, 78%, α/β 5:4) after size-exclusion chromatography (DCM/MeOH 1/1 v/v) and flash column chromatography (eluent: EtOAc/PE 1/4 \rightarrow 3/7); R_f 0.42 (EtOAc/PE, 2/3, v/v); IR (neat, cm⁻¹) 2870, 2106, 1801, 1761, 1717, 1497, 1454, 1028, 696; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.42–6.81 (m, 72H, H_{arom}), 5.67 (d, $J = 2.9$ Hz, 0.8H, H-1' β), 5.49 (d, $J = 2.5$ Hz, 1H, H-1' α), 5.45 (s, 0.8H, H-1'' β), 5.14–4.58 (m, 22H), 4.57–4.35 (m, 14.4H), 4.35–4.00 (m, 12.4H), 4.00–3.84 (m, 3.4H), 3.85–3.69 (m, 4.6H), 3.58–3.56 (m, 5.4H), 3.37 (dd, $J = 10.6, 3.9$ Hz, 0.8H, H-2 β), 3.31 (dd, $J = 10.6, 3.9$ Hz, 1H, H-2 α), 1.03–0.98 (m, 5.4H, H-6 α , H-6 β); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 173.5, 171.6, 168.0, 167.9, 156.7, 139.3, 138.5, 138.3, 138.1, 137.8, 137.3, 136.9, 136.8, 136.7, 136.2, 136.0, 135.1, 134.8, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.2, 127.1, 126.9, 99.9 (C-1' β), 97.7 (C-1 α , C-1 β), 95.2 (C-1'' α), 93.4 (C-1' α), 91.9 (C-1' β), 80.1, 79.0, 78.5, 77.2, 76.9, 76.4, 75.9, 75.8, 75.7, 75.4, 75.1, 74.7, 74.3, 74.0, 73.4, 73.0, 72.7, 72.4, 72.2, 72.1, 71.7, 71.4, 71.3, 71.2, 70.6, 70.3, 69.8 (C-3 β), 69.6 (C-3 α), 69.5, 68.1, 68.0, 67.1, 66.8, 66.7, 66.6, 65.1 (C-5 β , C-5 α), 59.5 (C-2 β), 59.1 (C-2 α), 50.8 (C-4 α), 50.7 (C-4 β), 16.3 (C-6 α), 16.2 (C-6 β); HRMS [M + Na]⁺ calcd for C₇₈H₈₀N₄O₁₈Na 1383.53598, found 1383.53760.

2,4-Di-O-benzyl- α / β -D-galactopyranosiduronyl-3,6-lactone-(1 \rightarrow 3)-benzyl 2,4-Di-O-benzyl- α -D-galactopyranosyluronate-(1 \rightarrow 3)-2-acetamido-4-(N-benzoyloxycarbonylamino)-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-1,2-di-O-benzyl-*sn*-glycerol (41). To an ice-cooled solution of 61 mg of epimeric azides 40 (45 μ mol) in 1.5 mL of pyridine was added 1.5 mL of freshly distilled thioacetic acid. The mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, and coevaporated with toluene. Flash column chromatography using EtOAc/PE (2/3) afforded title epimers 41 (25 mg, 18 μ mol, α/β 1:1, 40%); R_f 0.67 (EtOAc/PE, 3/2, v/v); IR (neat, cm⁻¹) 2930, 1802, 1718, 1668, 1497, 1454, 1027, 731, 695; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC) δ 7.48–6.84 (m, 80H, H_{arom}), 5.73 (dd, $J = 15.8, 9.2$ Hz, 2H, NH), 5.45 (s, 1H, H-1'' β), 5.29 (d, $J = 2.9$ Hz, 1H, H-1' α or H-1' β), 5.22–4.99 (m, 8H), 4.95 (d, $J = 12.4$ Hz, 1H), 4.87 (m, 2H), 4.79 (d, $J = 12.6$ Hz, 1H), 4.75–4.26 (m, 34H), 4.26–4.07 (m, 7H), 4.05–3.65 (m, 13H), 3.62–3.39 (m, 6H), 1.72 (s, 3H, CH₃ NHAc), 1.71 (s, 3H, CH₃ NHAc), 1.06 (m, 6H, H-6 α , H-6 β); ¹³C NMR (100 MHz, CDCl₃, HH-COSY, HSQC) δ 173.7, 171.7, 170.2, 170.1, 168.4, 168.2, 156.8, 139.3, 138.7, 138.2, 138.1, 138.0, 137.9, 137.8, 137.4, 136.9, 136.8, 136.4, 135.7, 135.0, 134.8, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 127.0, 126.9, 99.8 (C-1' β), 98.1 (C-1 α or C-1 β), 97.9 (C-1 α or C-1 β), 97.6 (C-1' α or C-1' β), 95.5 (C-1'' α), 95.4 (C-1' α or C-1' β), 80.0, 79.2, 77.3, 77.1, 76.8, 76.6, 76.0, 75.7, 75.5, 75.4, 75.0, 74.5,

74.2, 73.8, 73.7, 73.6, 73.5, 73.1, 72.4, 72.0, 71.9, 71.7, 71.6, 71.4, 71.2, 71.0, 70.6, 69.4, 69.3, 68.2, 67.1, 66.8, 66.5, 66.4, 65.7 (C-5 α or C-5 β), 65.5 (C-5 α or C-5 β), 52.5 (C-4 α or C-4 β), 52.1 (C-4 α or C-4 β), 48.8 (C-2 α or C-2 β), 48.5 (C-2 α or C-2 β), 22.9 (2 \times CH₃ NHAc), 16.5 (C-6 α , C-6 β); HRMS [M + Na]⁺ calcd for C₈₀H₈₄N₂O₁₉Na 1399.55605 C₂₉H₃₅N₃O₇S, found 1399.55602.

α -D-Galactopyranosyluronate-(1 \rightarrow 3)- α -D-galactopyranosyluronate-(1 \rightarrow 3)-2-acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-sn-glycerol (3a) and β -D-Galactopyranosyluronate-(1 \rightarrow 3)- α -D-galactopyranosyluronate-(1 \rightarrow 3)-2-acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-sn-glycerol (3b). To a solution of 35 mg (25 μ mol, 1 equiv) of epimeric mixture **41** in 1.5 mL of DCM was added 11.4 mg of TMSO₂Na (102 μ mol, 4 equiv). The mixture was stirred for 1 h, followed by evaporation and elution over a plug of silica (eluent: EtOAc, then EtOAc/MeOH/H₂O/AcOH 88/10/1/1). After removal of the eluent, the crude product was dissolved in *t*-BuOH/H₂O (4/1 v/v) and stirred under argon atmosphere. A catalytic amount of palladium on activated charcoal and 170 μ L of 1 M aq HCl were added, and the mixture was allowed to stir for 2 days under hydrogen atmosphere. Filtration over Celite, gel filtration (HW-40, 0.15 M Et₃NHOAc in H₂O), and ion-exchange column chromatography (30 mM NaOAc (aq)/100 mM NaOH (aq) \rightarrow 80 mM NaOAc (aq)/100 mM NaOH (aq)) yielded two fractions that were both subjected to another gel filtration step (HW-40, 0.15 M Et₃NHOAc in H₂O) to give the two title epimers in pure form after lyophilization (α -epimer **3a**: 4.4 mg, 7.0 μ mol 28% over two steps, β -epimer **3b**: 2.7 mg, 4.3 μ mol, 17% over two steps). α -Epimer **3a**: ¹H NMR (600 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 298 K) δ 5.17 (d, *J* = 3.1 Hz, 1H, H-1''), 5.07 (d, *J* = 2.6 Hz, 1H, H-1'), 4.89 (d, *J* = 3.8 Hz, 1H, H-1), 4.66 (s, 1H, H-5'), 4.46 (s, 1H, H-4'), 4.35 (q, *J* = 6.4 Hz, 1H, H-5), 4.31–4.25 (m, 2H, H-4'', H-3), 4.19–4.13 (m, 2H, H-2, H-5''), 3.99–3.93 (m, 3H, H-3', H-3'', H-2'), 3.93–3.89 (m, 1H, CH Gro), 3.87 (dd, *J* = 10.5, 3.2 Hz, 1H, H-2''), 3.82 (d, *J* = 4.0 Hz, 1H, H-4), 3.77 (dd, *J* = 10.6, 3.5 Hz, 1H, CH₂ Gro), 3.65 (dd, *J* = 11.7, 4.7 Hz, 1H, CH₂ Gro), 3.58 (dd, *J* = 11.7, 6.2 Hz, 1H, CH₂ Gro), 3.46 (dd, *J* = 10.5, 6.6 Hz, 1H, CH₂ Gro), 3.18 (q, *J* = 7.3 Hz, 1.2H, CH₂ Et₃NHOAc), 1.97 (s, 3H, CH₃ NHAc), 1.29 (d, *J* = 6.7 Hz, 3H, H-6), 1.26 (t, *J* = 7.3 Hz, 1.9H, CH₃ Et₃NHOAc); ¹³C NMR (151 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 298 K) δ 176.3, 175.5, 175.4 (C=O), 99.7 (C-1'), 98.3 (C-1), 97.4 (C-1''), 76.3 (C-3'), 73.8 (C-3), 73.0 (C-5''), 72.6 (C-5), 71.6 (C-4''), 71.4 (CH Gro), 70.4 (C-3''), 70.0 (CH₂ Gro), 68.8 (C-2''), 68.5 (C-4'), 66.7 (C-2'), 63.4 (C-5), 63.2 (CH₂ Gro), 53.7 (C-4), 48.7 (C-2), 47.6 (CH₂ Et₃NHOAc), 22.7 (CH₃ NHAc), 16.5 (C-6), 9.2 (CH₃ Et₃NHOAc); ¹³C-HMBC NMR (151 MHz, D₂O, T = 298 K) δ 99.7 (*J*_{C1'-H1'} = 170.3 Hz, C-1'), 98.3 (*J*_{C1-H1} = 173.6 Hz, C-1), 97.4 (*J*_{C1''-H1''} = 170.3 Hz, C-1''); HRMS [M + H]⁺ calcd for C₂₃H₃₉N₂O₁₈ 631.21924, found 631.21927. β -Epimer **3b**: ¹H NMR (600 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 298 K) δ 5.09 (d, *J* = 3.6 Hz, 1H, H-1'), 4.90 (d, *J* = 3.8 Hz, 1H, H-1), 4.61 (d, *J* = 7.8 Hz, 1H, H-1''), 4.58 (s, 1H, H-4'), 4.36 (q, *J* = 6.5 Hz, 1H, H-5), 4.29 (dd, *J* = 11.3, 4.4 Hz, 1H, H-3), 4.20–4.15 (m, 2H, H-4'', H-2), 4.14 (s, 1H, H-5'), 4.06 (s, 1H, H-5''), 4.05–3.98 (m, 2H, H-2', H-3'), 3.91 (dd, *J* = 9.6, 5.3 Hz, 1H, CH Gro), 3.84 (d, *J* = 3.7 Hz, 1H, H-4), 3.77 (dd, *J* = 10.6, 3.6 Hz, 1H, CH₂ Gro), 3.70 (dd, *J* = 10.0, 3.5 Hz, 1H, H-3''), 3.65 (dd, *J* = 11.7, 4.7 Hz, 1H, CH₂ Gro), 3.63–3.56 (m, 2H, CH₂ Gro, H-2''), 3.46 (dd, *J* = 10.6, 6.6 Hz, 1H, CH₂ Gro), 1.97 (s, 3H, CH₃ NHAc), 1.89 (s, 1H, CH₃ AcOH), 1.31 (t, *J* = 6.7 Hz, 3H, H-6); ¹³C NMR (151 MHz, D₂O, HH-COSY, HSQC, HMBC, TOCSY, T = 298 K) δ 176.1, 176.0, 175.5 (C=O), 104.7 (C-1''), 99.0 (C-1'), 98.3 (C-1), 80.3 (C-3'), 76.5 (C-5''), 73.6 (C-3''), 73.3 (C-3), 73.2 (C-5'), 71.5 (C-2''), 71.4 (CH Gro), 71.2 (C-4''), 70.7 (C-4'), 70.0 (CH Gro), 67.5 (C-2'), 63.2 (C-5), 53.7 (C-4), 48.7 (C-2), 22.7 (CH₃ NHAc), 16.5 (C-6); ¹³C-HMBC NMR (151 MHz, D₂O, T = 298 K) δ 104.7 (*J*_{C1''-H1''} = 161.5 Hz, C-1''), 99.0 (*J*_{C1'-H1'} = 170.0 Hz,

C-1'), 98.3 (*J*_{C1-H1} = 173.5 Hz, C-1); HRMS [M + H]⁺ calcd for C₂₃H₃₉N₂O₁₈ 631.21924, found 631.21923.

■ ASSOCIATED CONTENT

S Supporting Information. Spectroscopic data of the reported compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: marel_g@chem.leidenuniv.nl; jcodee@chem.leidenuniv.nl.

■ REFERENCES

- (1) (a) Mazmanian, S. K.; Kasper, D. L. *Nat. Rev. Immunol.* **2006**, *6*, 849–858. (b) Tzianabos, A. O.; Onderdonk, A. B.; Rosner, B.; Cisneros, R. L.; Kasper, D. L. *Science* **1993**, *262*, 416–419.
- (2) (a) Cobb, B. A.; Kasper, D. L. *Cell Microbiol.* **2005**, *7*, 1398–1403. (b) Cobb, B. A.; Wang, Q.; Tzianabos, A. O.; Kasper, D. L. *Cell* **2004**, *117*, 677–687.
- (3) (a) Hecht, M. L.; Stallforth, P.; Silva, D. V.; Adibekian, A.; Seeberger, P. H. *Curr. Opin. Chem. Biol.* **2009**, *13*, 354–359. (b) Pozsgay, V. *Curr. Top. Med. Chem.* **2008**, *8*, 126–140. (c) Vliegthart, J. F. G. *FEBS Lett.* **2006**, *580*, 2945–2950.
- (4) Velez, C. D.; Lewis, C. J.; Kasper, D. L.; Cobb, B. A. *Immunology* **2008**, *127*, 73–82.
- (5) (a) Cobb, B. A.; Kasper, D. L. *Glycobiology* **2008**, *18*, 707–718. (b) De Silva, R. A.; Wang, Q. L.; Chidley, T.; Appulage, D. K.; Andreana, P. R. *J. Am. Chem. Soc.* **2009**, *131*, 9622–9623.
- (6) (a) Wack, A.; Gallorini, S. *Immunopharm. Immunotechnol.* **2008**, *30*, 761–770. (b) Wang, Q.; McLoughlin, R. M.; Cobb, B. A.; Charrel-Dennis, M.; Zaleski, K. J.; Golenbock, D.; Tzianabos, A. O.; Kasper, D. L. *J. Exp. Med.* **2006**, *203*, 2853–2863.
- (7) van den Bos, L. J.; Boltje, T. J.; Provoost, T.; Mazurek, J.; Overkleeft, H. S.; van der Marel, G. A. *Tetrahedron Lett.* **2007**, *48*, 2697–2700.
- (8) (a) Velez, C. D.; Lewis, C. J.; Kasper, D. L.; Cobb, B. A. *Immunology* **2009**, *127*, 73–82. (b) Stephen, T. L.; Fabri, M.; Groneck, L.; Röhn, T. A.; Hafke, H.; Robinson, N.; Rietdorf, J.; Schrama, D.; Becker, J. C.; Plum, G.; Krönke, M.; Kropshofer, H.; Kalka-Moll, W. M. *PLoS Pathog.* **2007**, *3*, 11.
- (9) Groneck, L.; Schrama, D.; Fabri, M.; Stephen, T. L.; Harms, F.; Meemboor, S.; Hafke, H.; Bessler, M.; Becker, J. C.; Kalka-Moll, W. M. *Infect. Immun.* **2009**, *77*, 3705–3712.
- (10) Lindberg, B.; Lindqvist, B.; Lönngren, J.; Powell, D. A. *Carbohydr. Res.* **1980**, *78*, 111–117.
- (11) Pragani, R.; Stallforth, P.; Seeberger, P. H. *Org. Lett.* **2010**, *12*, 1624–1627.
- (12) (a) Pedersen, C. M.; Figueroa-Perez, I.; Boruwa, J.; Lindner, B.; Ulmer, A. J.; Zähringer, U.; Schmidt, R. R. *Chem.—Eur. J.* **2010**, *16*, 12627–12641. (b) Iynkkaran, I.; Bundle, D. R. *Carbohydr. Res.* **2010**, *345*, 2323–2327.
- (13) van den Bos, L. J.; Codée, J. D. C.; Litjens, R.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. *Eur. J. Org. Chem.* **2007**, 3963–3976.
- (14) (a) Magaud, D.; Grandjean, C.; Doutheau, A.; Anker, D.; Shevchik, V.; Cotte-Pattat, N.; Robert-Baudouy, J. *Tetrahedron Lett.* **1997**, *38*, 241–244. (b) Magaud, D.; Grandjean, C.; Doutheau, A.; Anker, D.; Shevchik, V.; Cotte-Pattat, N.; Robert-Baudouy, J. *Carbohydr. Res.* **1998**, *314*, 189–199. (c) Yamamoto, K.; Watanabe, N.; Matsuda, H.; Oohara, K.; Araya, T.; Hashimoto, M.; Miyairi, K.; Okazaki, I.; Saito, M.; Shimizu, T.; Kato, H.; Okuno, T. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4932–4935.
- (15) Wu, X. Y.; Cui, L. N.; Lipinski, T.; Bundle, D. R. *Chem.—Eur. J.* **2010**, *16*, 3476–3488.

- (16) Magaud, D.; Dolmazon, R.; Anker, D.; Doutheau, A.; Dory, Y. L.; Deslongchamps, P. *Org. Lett.* **2000**, *2*, 2275–2277.
- (17) See for conformationally restricted donors: (a) Pedersen, C. M.; et al. *C. R. Chim.* **2010**, doi: 10.1016/j.crci.2010.03.030. (b) Pedersen, C. M.; Marinescu, L. G.; Bols, M. *Chem. Commun.* **2008**, 2465–2467. (c) Pedersen, C. M.; Nordström, L. U.; Bols, M. *J. Am. Chem. Soc.* **2007**, *129*, 9222–9235.
- (18) O'Brien, C.; Polakova, M.; Pitt, N.; Tosin, M.; Murphy, P. V. *Chem.—Eur. J.* **2007**, *13*, 902–909.
- (19) van den Bos, L. J.; Litjens, R.; van den Berg, R. J. B. H. N.; Overkleeft, H. S.; van der Marel, G. A. *Org. Lett.* **2005**, *7*, 2007–2010.
- (20) *The Organic Chemistry of Sugars*; Levy, D. E., Fügedi, P., Eds.; CRC Press: New York, 2006.
- (21) Chi, F. C.; Kulkarni, S. S.; Zulueta, M. M. L.; Hung, S. C. *Chem. Asian J.* **2009**, *4*, 386–390.
- (22) The glycerol diol can potentially be transformed into a suitable conjugation handle after oxidative cleavage or selective ketal/acetal formation.
- (23) (a) Chao, C. S.; Chen, M. C.; Lin, S. C.; Mong, K. K. T. *Carbohydr. Res.* **2008**, *343*, 957–964. (b) Ohlsson, J.; Magnusson, G. *Carbohydr. Res.* **2000**, *329*, 49–55.
- (24) Du, Y. G.; Zhang, M. M.; Kong, F. Z. *Org. Lett.* **2000**, *2*, 3797–3800.
- (25) van den Bos, L. J.; Codée, J. D. C.; van der Toorn, J. C.; Boltje, T. J.; van Boom, J. H.; Overkleeft, H. S.; van der Marel, G. A. *Org. Lett.* **2004**, *6*, 2165–2168.
- (26) (a) Epp, J. B.; Widlanski, T. S. *J. Org. Chem.* **1999**, *64*, 293–295. (b) De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. *J. Org. Chem.* **1997**, *62*, 6974–6977.
- (27) Fernandez-Mayoralas, A.; Marra, A.; Trumtel, M.; Veyrières, A.; Sinaÿ, P. *Carbohydr. Res.* **1989**, *188*, 81–95.
- (28) Attempts to transform phenyl 2-O-benzyl-1-deoxy-1-thio- β -D-galactose into lactone **5** using a TEMPO/BAIB-mediated oxidation failed, probably due to the presence of the *cis*-diol function.
- (29) Griffin, A. M.; Newcombe, N. J.; Alker, D.; Ramsay, M. V. J.; Gallagher, T. *Heterocycles* **1993**, *35*, 1247–1258.
- (30) A HMBC crosspeak between C-6 and H-3 served as an affirmation of the assignment of H-3.
- (31) Constantino, M. G.; Lacerda, V., Jr.; da Silva, G. V. J.; Tasic, L.; Rittner, R. *J. Mol. Struct.* **2001**, *597*, 129–136.
- (32) See for previous syntheses: (a) Cai, Y.; Ling, C. C.; Bundle, D. R. *J. Org. Chem.* **2009**, *74*, 580–589. (b) Liang, H.; Grindley, T. B. *J. Carbohydr. Chem.* **2004**, *23*, 71–82. (c) Medgyes, A.; Farkas, E.; Liptak, A.; Pozsgay, V. *Tetrahedron* **1997**, *53*, 4159–4178. (d) Smid, P.; Jörning, W. P. A.; van Duuren, A. M. G.; Boons, G.; van der Marel, G. A.; van Boom, J. H. *J. Carbohydr. Chem.* **1992**, *11*, 849–865. (e) Hermans, J. P. G.; Elie, C. J. J.; van der Marel, G. A.; van Boom, J. H. *J. Carbohydr. Chem.* **1987**, *6*, 451–462. (f) Lonngren, H.; Lonngren, J. *Carbohydr. Res.* **1984**, *132*, 39–44. (g) Liav, A.; Jacobson, I.; Sheinblatt, M.; Sharon, N. *Carbohydr. Res.* **1978**, *66*, 95–101.
- (33) Full experimental details of the large-scale synthesis of building block **6** will be reported elsewhere.
- (34) Yu, B.; Tao, H. C. *Tetrahedron Lett.* **2001**, *42*, 2405–2407.
- (35) (a) Figueroa-Perez, I.; Stadelmaier, A.; Morath, S.; Hartung, T.; Schmidt, R. R. *Tetrahedron-Asymmetr.* **2005**, *16*, 493–506. (b) van Boeckel, C. A. A.; Visser, G. M.; van Boom, J. H. *Tetrahedron* **1985**, *41*, 4557–4565. (c) Stadelmaier, A.; Morath, S.; Hartung, T.; Schmidt, R. R. *Angew. Chem., Int. Ed.* **2003**, *42*, 916–920.
- (36) (a) Demchenko, A. V. *Synlett* **2003**, 1225–1240. (b) Demchenko, A. V.; Rousson, E.; Boons, G.-J. *Tetrahedron Lett.* **1999**, *40*, 6523–6526. (c) Ishiwata, A.; Munemura, Y.; Ito, Y. *Tetrahedron* **2008**, *64*, 92–102. (d) Eby, R.; Schuerch, C. *Carbohydr. Res.* **1974**, *34*, 79–90.
- (37) (a) Codée, J. D. C.; van den Bos, L. J.; Litjens, R.; Overkleeft, H. S.; van Boeckel, C. A. A.; van Boom, J. H.; van der Marel, G. A. *Tetrahedron* **2004**, *60*, 1057–1064. (b) Codée, J. D. C.; Litjens, R.; den Heeten, R.; Overkleeft, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5*, 1519–1522. (c) Garcia, B. A.; Gin, D. Y. *J. Am. Chem. Soc.* **2000**, *122*, 4269–4279. (d) Garcia, B. A.; Poole, J. L.; Gin, D. Y. *J. Am. Chem. Soc.* **1997**, *119*, 7597–7598.
- (38) The use of undistilled thiolacetic acid sometimes resulted in the concomitant acetylation of the free C-3'' hydroxyl function in **28**.
- (39) Seden, P. T.; Charmant, J. P. H.; Willis, C. L. *Org. Lett.* **2008**, *10*, 1637–1640.
- (40) Steliou, K.; Szczygielska-Nowosielska, A.; Favre, A.; Poupart, M. A.; Hanessian, S. *J. Am. Chem. Soc.* **1980**, *102*, 7578–7579.
- (41) Walvoort, T. C.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Org. Chem.* **2010**, *75*, 7990–8002.